

DOCKET NO.: CP380F (CEPH-3138)
Application No.: 10/776,504
Office Action Dated: June 2, 2006

PATENT RECEIVED
CENTRAL FAX CENTER

NOV 01 2006

REMARKS

Following entry of the foregoing amendments, claims 1, 3 to 12, 19 to 22, and 24 will be pending in the application. Claims 1, 3 to 9, 11, 12, 19 to 22, and 24 have been amended, and claims 2, 13 to 18, and 23 have been canceled, herein, without prejudice. No new claims have been added. The first paragraph of the specification has been amended to update the status of the parent application. Support for the amendments is found throughout the specification as originally filed, and the amendments thus do not introduce new matter into the application.

Applicants respectfully request reconsideration of the rejections of record in view of the foregoing amendments and the following remarks.

Alleged Indefiniteness

Claim 11 has been rejected under 35 U.S.C. § 112, second paragraph as allegedly indefinite because the claim recites all-trans retinoic acid as a "further therapeutic agent," while claim 1, from which claim 11 depends, already recites the administration of all-trans retinoic acid. Claim 11 has been amended to correct the inadvertent error by removing "all-trans retinoic acid," thus obviating the rejection. Applicants accordingly, respectfully request withdrawal thereof.

Alleged Anticipation

Claims 1 to 7, 13 to 15, 20, 21, and 24 have been rejected under 35 U.S.C. § 102(a) as anticipated by Shen, *et al.*, *Blood*, 1997, 89(9), 3354-3360 ("the Shen article") because the article allegedly describes treatment of acute promyelocytic leukemia (APL) with both arsenic trioxide and all-trans retinoic acid. Without conceding the correctness of the rejection, and to advance prosecution, claim 1 has been amended to recite treatment of acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia. Support for the amendments is found throughout the specification as originally filed, including, for example, page 21, lines 7 to 9. The present claims thus do not recite treatment of APL, and the Shen article thus fails to anticipate the presently claimed subject matter. Applicants accordingly, respectfully request withdrawal of the rejection.

Alleged Obviousness

Page 5 of 10

BEST AVAILABLE COPY

DOCKET NO.: CP380F (CEPH-3138)
Application No.: 10/776,504
Office Action Dated: June 2, 2006

PATENT

A. Claims 1 to 16, 19 to 22, and 24 have been rejected under 35 U.S.C. § 103(a) as allegedly obvious over the Shen article in view of Chen, *et al.*, *Blood*, 1997, 89(9), 3345-3353 ("the Chen article"), Kwong, *et al.*, *Blood*, 1997, 89, 348703488 ("the Kwong article"), and Medline abstract number 91278513 ("the Wiernki abstract"). Applicants respectfully request reconsideration and withdrawal of the rejection because the presently claimed subject matter would not have been obvious in view of the cited art.

To establish *prima facie* obviousness, the Patent Office must provide objective evidence that the prior art relied upon, coupled with the knowledge generally available in the art at the time of the invention, contains some suggestion or incentive that would have motivated those of ordinary skill in the art to modify a reference or to combine references. *In re Lee*, 61 U.S.P.Q.2d 1430, 1433 (Fed. Cir. 2002); *In re Fine*, 837 F.2d 1071, 1074, 5 U.S.P.Q.2d 1596, 1598 (Fed. Cir. 1998). And the proposed modification or combination of the prior art *must have had a reasonable expectation of success*, determined from the vantage point of those of ordinary skill in the art, at the time the invention was made. *Amgen, Inc. v. Chugai Pharm. Co.*, 927 F.2d 1200, 1209, 18 U.S.P.Q.2d 1016, 1023 (Fed. Cir. 1991).

"[W]hether a particular combination might be 'obvious to try' is not a legitimate test of patentability." *In re Fine*, 837 F.2d 1071, 1075 (Fed. Cir. 1988). "Obvious to try" situations arise where it might have been obvious to "explore a new technology or general approach that seemed to be a promising field of experimentation, where the prior art gave only general guidance as to the particular form of the claimed invention or how to achieve it." *In re O'Farrell*, 853 F.2d 894, 903 (Fed. Cir. 1988). *See also Hybritech Inc. v. Monoclonal Antibodies, Inc.*, 802 F.ed. 1367, 1380 (Fed. Cir. 1986)(stating that "At most, these articles are invitations to try monoclonal antibodies in immunoassays but do not suggest how that end might be accomplished.") (emphasis in original).

Preliminarily, as discussed above, claim 1 has been amended to recite methods for the treatment of acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia in a human, that comprise administering to the human a combination of a therapeutically effective amount of arsenic trioxide, and all-trans retinoic acid.

Upon review of the references cited in the Office action, those skilled in the art would not have reasonably expected at the time of the invention that a combination of arsenic trioxide and

DOCKET NO.: CP380F (CEPH-3138)

PATENT

Application No.: 10/776,504

Office Action Dated: June 2, 2006

all-trans retinoic acid could have been successfully used to treat acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia in humans. At most, it might have been obvious to persons skilled in the art *to try* to use a combination of arsenic trioxide and all-trans retinoic acid to treat these cancers, but much more is required to establish *prima facie* obviousness.

The Shen article describes treatment of 15 patients having relapsed APL with arsenic trioxide.¹ Two of the fifteen patients were also treated with low-dose all-trans retinoic acid.² Notably, the article only describes treatment of patients having APL, and does not describe or suggest treatment of cancers other than APL with a combination of arsenic trioxide and all-trans retinoic acid.

The Chen article describes the treatment of patients suffering from APL with arsenic trioxide.³ The article does not teach or suggest treatment of APL with a combination of arsenic trioxide and all-trans retinoic acid, much less teach or suggest treatment of cancers other than APL with a combination of arsenic trioxide and all-trans retinoic acid.

The Kwong article describes studies in which patients having relapsed APL were treated with arsenic trioxide.⁴ The article describes further studies in which patients having chronic myeloid leukemia (CML) were treated with arsenic trioxide.⁵ Again, the article fails to teach or suggest treatment of patients suffering from APL, CML, or any type of cancer, with a combination of arsenic trioxide and all-trans retinoic acid.

Finally, the Wiernik abstract describes studies in which patients having APL were treated with all-trans retinoic acid. The abstract also describes that treatment of a patient having CML with all-trans retinoic acid. The abstract fails to teach or suggest treatment of cancers other than APL and CML with all-trans retinoic acid, and, moreover, fails to teach or suggest treatment of any type of cancer with a combination of arsenic trioxide and all-trans retinoic acid.

The references cited in the Office action thus fail to teach or suggest that a combination of arsenic trioxide and all-trans retinoic acid could be successfully used to treat acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute

¹ Page 3354; second column.

² *Id.*

³ Page 3348; second column.

⁴ Page 3487; first column.

⁵ Page 3487; second column.

DOCKET NO.: CP380F (CEPH-3138)
Application No.: 10/776,504
Office Action Dated: June 2, 2006

PATENT

erythroleukemia in humans. Rather, the references teach that arsenic trioxide and all-trans retinoic acid have been administered in combination to humans to treat acute promyelocytic leukemia. The references also teach that arsenic trioxide and all-trans retinoic acid have been used separately to treat patients suffering from CML, but the references do not teach that a combination of arsenic trioxide and all-trans retinoic acid have been successfully used to treat CML patients or patients suffering from acute myelocytic leukemias other than APL.

As understood by those skilled in the art at the time of the invention, there are many different types of acute and chronic myelocytic leukemias, and different approaches have been taken towards treating the different types of acute and chronic myelocytic leukemias. For example, according to the widely accepted French-American-British (FAB) classification, acute myelocytic leukemias (AMLs) have been divided into seven subclasses.⁶ APL is classified as the third AML subtype, or AML-M3.⁷ Treatment of AML has primarily consisted of chemotherapy divided into two phases, induction and postremission (or consolidation) therapy. The goal of induction therapy is to achieve a complete remission by reducing the amount of leukemic cells to an undetectable level, and the goal of consolidation therapy is to eliminate any residual undetectable disease and achieve a cure. Patients with AML subtypes other than M3 (APL) have typically been given induction chemotherapy with cytarabine and an anthracycline (such as daunorubicin).⁸ M3 AML (APL), however, has been almost universally treated with ATRA in addition to induction chemotherapy.⁹ Patients having non-APL AML's have thus typically received treatment that differs from that given to APL patients. Accordingly, those skilled in the art would have appreciated at the time of the invention that the efficacy of a particular anti-cancer agent or agents against APL was not predictive of its efficacy against other subtypes of AML due to the different approaches that have proven successful for treating APL and non-APL AML's.

Those skilled in the art would thus not have reasonably expected that a combination of arsenic trioxide and all-trans retinoic acid could have been successfully used to treat non-APL AML subtypes in humans just because the combination had been reported to have efficacy

⁶ Bruserud, O., *et al.*, *Stem Cells*, 2000, 18, 157-165 (attached as Exhibit A). See page 157, second column.

⁷ *Id.*

⁸ Appelbaum, F.R., *et al.*, *Hematology*, 2001, 62-86 (attached as Exhibit B). See page 65.

⁹ *Id.* at 63.

DOCKET NO.: CP380F (CEPH-3138)
Application No.: 10/776,504
Office Action Dated: June 2, 2006

PATENT

against APL. Although those skilled in the art might arguably have considered trying to use a combination of arsenic trioxide and all-trans retinoic acid to treat acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia, the results of doing so could not have been predicted with a reasonable degree of certainty. Accordingly, those skilled in the art at the time of the invention would not have reasonably expected that a combination of arsenic trioxide and all-trans retinoic acid could have been successfully used to treat acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia in humans.

Applicants thus respectfully submit that the presently claimed subject matter would not have been obvious at the time of the invention, and Applicants, accordingly, respectfully request withdrawal of the rejection.

B. Claims 1 to 16, 19 to 22, and 24 have been rejected under 35 U.S.C. § 103(a) as allegedly obvious over the Shen article in view of the Chen article, the Kwong article, the Wiernki abstract, and U.S. Patent number 4,599,305 ("the Witte patent"). Applicants respectfully request reconsideration and withdrawal of the rejection because the presently claimed subject matter would not have been obvious in view of the cited art.

As discussed above, upon review of the Shen, Chen, and Kwong articles and the Wiernki abstract, those skilled in the art would not have reasonably expected at the time of the invention that a combination of arsenic trioxide and all-trans retinoic acid could have been successfully used to treat acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia in humans, and the Witte patent does not cure the deficiencies of these references. The Witte patent teaches that different therapies are utilized for the treatment of different types of leukemias, and states that acute leukemia requires immediate treatment utilizing the full range of therapeutic measures available.¹⁰ The patent, however, does not teach or suggest that the "full range of therapeutic measures" includes a combination of arsenic trioxide and all-trans retinoic acid. Moreover, the patent does not describe or suggest treatment of acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia with a combination of arsenic trioxide and all-trans retinoic acid.

¹⁰ Col. 1, lns. 39 to 45.

DOCKET NO.: CP380F (CEPH-3138)
Application No.: 10/776,504
Office Action Dated: June 2, 2006


PATENT

Accordingly, for the reasons discussed above, those skilled in the art at the time of the invention would not have reasonably expected that a combination of arsenic trioxide and all-trans retinoic acid could have been successfully used to treat acute myeloblastic leukemia, acute myelomonocytic leukemia, acute monocytic leukemia, and acute erythroleukemia in humans. The presently claimed subject matter would thus not have been obvious, and Applicants accordingly, respectfully request withdrawal of the rejection.

Conclusion

Applicants believe that the foregoing constitutes a complete and full response to the Office action of record. Accordingly, an early and favorable action is respectfully requested.

Respectfully submitted,



Christy Cheever
Attorney of Record
Registration No. 52,722

Date: November 1, 2006

Cephalon, Inc.
41 Moores Road
P.O. Box 4011
Frazer, PA 19355
Telephone: (610) 883-5743
Facsimile: (610) 727-7651



Acute Myeloid Leukemia

Frederick R. Appelbaum, Jacob M. Rowe, Jerald Radich, and John E. Dick

Through the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies. How these new therapies can be most effectively studied in the clinic and whether they will ultimately improve cure rates are questions of enormous importance. In this article, Dr. Jacob Rowe presents a summary of the current state-of-the-art therapy for adult AML. His contribution emphasizes the fact that AML is not a single disease, but a number of related diseases each distinguished by unique cytogenetic markers which in turn help determine the most appropriate treatment. Dr. Jerald Radich continues on this theme, emphasizing how these cytogenetic abnormalities, as well as other mutations, give rise to abnormal signal transduction and

how these abnormal pathways may represent ideal targets for the development of new therapeutics. A third contribution by Dr. Frederick Appelbaum describes how AML might be made the target of immunologic attack. Specifically, strategies using antibody-based or cell-based immunotherapies are described including the use of unmodified antibodies, drug conjugates, radioimmunoconjugates, non-ablative allogeneic transplantation, T cell adoptive immunotherapy and AML vaccines. Finally, Dr. John Dick provides a review of the development of the NOD/SCID mouse model of human AML emphasizing both what it has taught us about the biology of the disease as well as how it can be used to test new therapies. Taken together, these reviews are meant to help us understand more about where we are in the treatment of AML, where we can go and how we might get there.

I. CURRENT STANDARD THERAPY OF ADULT ACUTE MYELOID LEUKEMIA

*Jacob M. Rowe, MD**

Despite important advances in the therapy of acute myeloid leukemia (AML) the majority of patients will die from their disease (Figure 1). Progress in therapy and supportive care over the past three decades has led to gradual improvement in the overall results, especially in adults up to age 55-60 years (Figure 2). However, very little progress has been made in the long-term survival of older adults with AML (Figure 3). Since the median age of patients with AML is 64 years, this older group of patients represents the majority with this disease, and the outcome of therapy remains frustratingly disappointing. This section will review current strategies for induction and post-remission therapy focusing on newly diagnosed younger adults. Possible strategies for older adults will then be discussed briefly.

It is no longer appropriate to consider all subgroups of AML as a single entity. The most important prognostic factors determining the outcome of therapy are the acquired genetic changes in the leukemia cells; determined by conventional cytogenetic techniques, fluorescence in situ hybridization (FISH) analysis or polymerase chain reaction (PCR). Thus, the following discussion will focus on acute promyelocytic leukemia (APL) and all other AMLs divided into three recognized prognostic groups: those exhibiting favorable, intermediate or unfavorable cytogenetics at presentation (Table 1).

Acute Promyelocytic Leukemia—t(15;17)—PML-RAR α

APL is the subtype of acute leukemia where the greatest progress has been made over the past decade. It is the most curable subtype of AML and the most important development leading to the dramatic improvement in survival has been the introduction of all-trans retinoic acid (ATRA). While the incorporation of ATRA has led to these remarkable results, differentiation therapy with ATRA is associated with unique toxicities not previously observed with conventional cytotoxic therapy.

* Department of Hematology and Bone Marrow Transplant, Rambam Medical Center, Haifa, 31096, Israel




Figure 1. Survival of almost 3,000 consecutive patients treated on ECOG protocols for newly diagnosed acute myeloid leukemia (AML) since 1973. The only exclusion from this curve is acute promyelocytic leukemia (APL) patients treated on all-trans retinoic acid (ATRA).




Figure 2. Patients ≤ 55 years with newly diagnosed acute myeloid leukemia (AML) treated on Eastern Cooperative Oncology Group (ECOG) protocols since 1973.




Figure 3. Patients > 55 years with newly diagnosed acute myeloid leukemia (AML) treated on Eastern Cooperative Oncology Group (ECOG) protocols since 1973.

Induction therapy

Historically, induction therapy for APL included an anthracycline and cytarabine. APL was known to be particularly sensitive to anthracyclines, in part due to significantly lower Pgp expression and other resistance markers in APL cells compared to other subtypes of AML.¹ It may also be that for this reason the long-term results in APL with conventional chemotherapy have historically been significantly better than in other forms of AML.²

Several studies have confirmed that both daunorubicin and idarubicin, used as single agents, induce a CR in 60%-80% of patients.^{3,4} Importantly, a retrospective analysis by the Southwest Oncology Group (SWOG) showed an improved survival in patients with APL when the dose of anthracycline was increased (70 mg/m²) but without a change in cytarabine dose.⁵ It has now been established that ATRA is an important part of induction therapy for APL. The benefit of ATRA in induction may not necessarily be a dramatic change in the initial CR rate;⁶ rather, incorporation of ATRA has a major impact on the number of patients that may be cured in this disease.^{7,9}

Several studies have shown that when ATRA is combined with single-agent anthracycline the results are at least as good as when cytarabine is also added.^{4,10} It is likely that the standard form of induction therapy for APL will rely on ATRA with an anthracycline without the addition of cytarabine (Table 2). Despite theoretic considerations, there is no evidence for the superiority of any anthracycline in APL. Using ATRA and an anthracycline, a CR rate of greater than 80% may be reasonably expected. However, despite the remarkable impact of ATRA in the treatment of AML, the induction mortality remains approximately 10%, and acquired retinoid resistance contributes to relapse in approximately 20-30% of patients.^{7-9,11}

While the incidence of coagulopathy and bleeding have diminished significantly with ATRA therapy, the retinoic acid syndrome (RAS) is now the major toxicity associated with ATRA. Among patients treated with ATRA alone the incidence is approximately 15%. The mortality from this syndrome has declined over time, likely reflecting earlier recognition and institution of dexamethasone. Furthermore, the concurrent administration of chemotherapy with ATRA may decrease the incidence of RAS.¹²

Table 1. Cytogenetic classification.

| | SWOG Criteria ²⁷ | MRC criteria ² : As for SWOG, except: - |
|--------------|---|--|
| Favorable | t(15;17) – with any other abnormality inv(16)t(16;16)/del(16q) – with any other abnormality t(8;21) – without del(9q) or complex karyotype | t(8;21) – with any other abnormality |
| Intermediate | +8, -Y, +6, del(12p) normal karyotype | abn 11q23 del(9q), del(7q) – without other abnormalities Complex karyotypes (≥ 3 abnormalities, but < 5 abnormalities) All abnormalities of unknown prognostic significance |
| Unfavorable | -5/del(5q), -7/del(7q), t(8;21) with del(9q) or complex karyotype inv(3q), abn 11q23, 20q, 21q, del(8q), t(6;9) t(9;22), abn 17p, Complex karyotypes (≥ 3 abnormalities) | Complex karyotypes (≥ 5 abnormalities) |
| Unknown | All other clonal chromosomal aberrations with fewer than 3 abnormalities | |

Abbreviations: SWOG, Southwestern Oncology Group; MRC, Medical Research Council; abn, abnormalities of

Post-remission therapy

Although CR may be achieved using ATRA alone, most patients relapse with this therapy. Consolidation chemotherapy after CR is mandatory, although the best form of such therapy is unknown. In most studies consolidation chemotherapy has been anthracycline-based, and several studies have included high-dose cytarabine.^{7,9,12} However, the administration of lower doses of cytarabine appears to be just as efficacious,¹³ and a recent prospective study has suggested that patients do as well without cytarabine in either induction or consolidation.¹⁰ Thus, it is likely that, just as in induction, there is probably little role for cytarabine in consolidation, although this remains a subject of study in current clinical trials. Most centers administer at least two courses of post-remis-

sion therapy following induction with ATRA and anthracyclines, although, as in all types of AML, there are no prospective data establishing the number of courses of intensive post-remission consolidation.¹⁴ Clearly, the objective of post-remission therapy is complete eradication of the leukemic clone with lack of detection of PML-RARα by PCR. This remains critical as the persistence of such minimal residual disease predicts for relapse.⁹

Maintenance therapy

Randomized trials have suggested that maintenance therapy with ATRA is a critical component of therapy for APL.^{7,8} There has also been a suggestion that when ATRA maintenance is combined with low-dose chemotherapy this may further improve the long-term survival.⁶

Thus, it appears that patients with APL may benefit from maintenance ATRA, with or without continuous low-dose chemotherapy, particularly those patients who present with higher risk for recurrent disease.⁸

Investigational approaches

While the outlook for patients with APL has improved dramatically over the past decade, complacency is to be discouraged. Over 20% of patients presenting with APL will die from this disease. This includes some pa-

Table 2. Treatment of acute promyelocytic leukemia [t(15;17) or PML-RARα positive].

| | |
|-------------------------------|---|
| INDUCTION | ATRA + anthracycline-based chemotherapy (i) anthracycline alone if cannot give ATRA (ii) probably, no need for cytarabine |
| CONSOLIDATION | Anthracycline-based chemotherapy x 1 – 2 cycles role of cytarabine unproven |
| MAINTENANCE | ATRA ± low-dose chemotherapy |
| Current investigation | Role of arsenic in patients who have not relapsed |
| Possible future investigation | Role of autologous PBSC transplants in patients who have become negative for PML-RARα |

Abbreviations: ATRA, all-trans retinoic acid; PBSC, peripheral blood stem cell

tients who relapse even after achieving PML-RAR α molecular negativity after induction and consolidation therapy.⁹ Arsenic trioxide has been established as an important agent for the treatment of ATRA-resistant APL. Whether this should be incorporated into the therapy of newly diagnosed APL is being currently investigated in clinical trials.

Allogeneic stem cell transplant has no role in APL in first remission. However, impressive results have been shown using autologous transplant for relapsed APL using cells that are molecularly negative.¹⁵ This has never been prospectively studied in patients in first remission who have been successfully treated with ATRA-anthracyclines. It is speculative whether such therapy, using peripheral blood with its attendant low mortality, can further improve the long-term cure rate.

Therapy for Acute Myeloid Leukemia Other Than Acute Promyelocytic Leukemia

Induction therapy

Classic studies by the CALGB two decades ago resulted in the development of the standard induction regimen, which consists of daunorubicin, 45mg i.v. for three days, and cytarabine, 100mg i.v. by continuous infusion for seven days.¹⁶ For patients less than 55 to 60 years old, an initial CR of 60-75% can be expected. However, multiple randomized studies compared daunorubicin at a dose of 45mg/m²—while keeping the dose of cytarabine constant—with idarubicin,¹⁷ amsacrine,¹⁸ aclacinomycin A¹⁹ and mitoxantrone.²⁰ Virtually all of these agents have been shown to be either unequivocally superior, or at least with a strong trend towards an improvement, when compared with 45mg/m² of daunorubicin. Thus, for patients not treated on a clinical trial it is no longer appropriate to use 45mg/m² of daunorubicin; rather, a higher dose of daunorubicin should be used or an alternative anthracycline or anthraquinone, such as idarubicin or mitoxantrone.

Over the years many variations of the standard 3+7 regimen have been developed and all yield approximately similar results. Intensifying induction therapy through the use of higher doses of cytarabine or the addition of etoposide, while not affecting the initial CR, clearly may have an effect on the disease-free survival.²¹ However, although intensifying induction therapy may affect the duration of remission in AML, it is not clear that the increased toxicity through more profound myelosuppression is advantageous given the possibility that a similar intensification might be safely added during postremission therapy.²²

Currently, the 3+7 induction regimen is rec-

ommended for all newly diagnosed patients with AML, including those who present with unfavorable cytogenetics. The latter group also includes most patients with therapy-related or other secondary leukemias. Although multiple publications have advocated alternative regimens,²³ there are no data that any form of therapy provides a better outcome than standard induction therapy consisting of an anthracycline and cytarabine. Three large cooperative groups that evaluated this reported CR rates of 55-58% in adult patients presenting with unfavorable cytogenetics (Table 3).^{22,24-27}

Postremission Therapy

While induction therapy may be identical, the choice of postremission therapy must be determined by the prognostic group, most importantly, the cytogenetics at presentation (Table 4).

AML with favorable cytogenetics

Although over the past decade there have been several large prospective studies^{24-26,28} of postremission therapy in AML, only two of the large studies have rigorously analyzed post-remission data by cytogenetic prognostic groups.^{22,27} The initial response rate to induction in patients with favorable cytogenetics was approximately 85%. With intensive postremission therapy the overall survival at 5 years exceeds 50%.^{2,27} There are many chemotherapeutic strategies for postremission therapy, although it is thought by many that high-dose cytarabine is a critical element for the success of postremission therapy.²⁹ However, while the data confirm its effectiveness as postremission therapy, it is doubtful that we need to subscribe to a dogma that one cannot do the same with other regimens. A recent publication, based on CALGB data, suggested that it may be inappropriate not to administer 3-4 cycles of high-dose cytarabine to patients with the t(8;21) abnormality, in which the disease-free survival was about 60%.²⁹ However, the MRC re-

Table 3. Results of induction therapy in adults with acute myeloid leukemia according to cytogenetic prognostic groups.

| | Favorable n | CR | Intermediate n | CR | Unfavorable n | CR |
|---------------------------------------|----------------|-----|-------------------|-----|------------------|-----|
| MRC ² (excluding children) | 289 | 80% | 853 | 84% | 130 | 57% |
| ECOG/SWOG ²⁷ | 121 | 84% | 278 | 76% | 184 | 55% |
| GOELAM ²⁴ | 48 | 87% | 226 | 76% | 36 | 58% |

Results of induction therapy from 3 cooperative groups. Identical standard induction therapy was used in all cytogenetic subtypes. A remarkable concordance among the 3 groups is demonstrated, although a rigorous comparison cannot be made due to minor differences among the studies in the classification of the cytogenetic prognostic groups.

Abbreviations: MRC, Medical Research Council; ECOG, Eastern Cooperative Oncology Group; SWOG, Southwestern Oncology Group; GOELAM, Groupe Ouest-Est Leukemies Aigues Myeloblastiques

Table 4. Suggested schema for the post-remission therapy of adults with newly diagnosed acute myeloid leukemia (except APL) according to cytogenetic prognostic groups.

| Induction | Favorable Intermediate Unfavorable | | |
|--|--|--|---|
| | Standard anthracycline + cytarabine (3 + 7) or similar | | |
| Post Remission Therapy | Allogeneic transplant as soon as possible | | |
| | High-dose cytarabine or similar x 2-3 cycles | High-dose cytarabine or similar x 2-3 cycles autologous transplant | High-dose cytarabine or similar x 2-3 cycles ± autologous transplant |
| (i) HLA-matched family donor available | High-dose cytarabine or similar x 2-3 cycles | | |
| (ii) No donor | ± autologous peripheral stem cell transplant | High-dose cytarabine or similar x 2-3 cycles autologous transplant | High-dose cytarabine or similar x 2-3 cycles ± autologous transplant |
| Future Investigations | | | |
| | Addition of gemtuzumab, ozogamicin either to intensive chemotherapy or pre-autologous transplant | | Allogeneic transplant from alternative donors – matched unrelated (MUD) or haploidentical |

ported an identical disease-free survival in a much larger cohort of patients without using high-dose cytarabine.^{2,25}

Whether autologous stem cell transplantation should be offered as a part of postremission strategy to patients with favorable cytogenetics remains controversial. Data from the CALGB have suggested that intensive chemotherapy yields results that are unlikely to be improved by the substitution of autologous transplantation.²⁹ In contrast, the US Intergroup Study^{26,27} suggested that autologous transplantation may be particularly useful in this group of patients. In the MRC AML 10 study, patients were randomized to receive autologous stem cell transplant after four cycles of therapy and this was compared with an observation arm.²⁵ The patients with favorable cytogenetics had a markedly lower relapse rate than patients who did not receive an autologous transplant, although a high procedural mortality rate in adults (18%) resulted in being ultimately no difference in the overall survival. The reported data need to be cautiously interpreted and may be influenced by small cohorts of patients, as in the CALGB data²⁹ or the US Intergroup Study.²⁶ Except for young patients in whom fertility remains a consideration, it is probably reasonable to use peripheral autologous stem cell transplantation in experienced centers that have demonstrated a consistently low morbidity and a therapy-related mortality of less than 3-5%.

None of the randomized studies demonstrated an advantage for allogeneic transplant for this group of patients, and given the relatively high transplant-related mortality, this procedure cannot be recommended as standard therapy for such patients. Whether newer methods using less severely myeloablative regimens and relying on the immunological effect of GVL may yield improved results remains to be determined in prospective studies.³⁰

AML with intermediate risk cytogenetics

If an HLA-matched family donor is available, it seems likely that this should be the recommended therapy for patients up to age 55-65 years. Data have consistently shown that this form of therapy provides the best anti-leukemic effect as judged by the relapse rate.^{31,32} The study with the largest cohort of prospectively evaluated patients with this subgroup of AML have reported a 3-year survival rate of 65% with a relapse risk at 3 years of 18%.^{2,25} It should be noted, however, that this advantage for allogeneic transplant was not demonstrated in the US Intergroup Study,^{26,27} albeit in a smaller cohort of patients.

Timing of allogeneic transplantation in first remission has never been prospectively established. For logistic reasons it may often be necessary to administer chemotherapy after achievement of CR until the availability of a donor and transplant center is established. However, retrospective analysis from the IBMTR suggests that for patients proceeding to allogeneic transplantation in AML there is no added benefit in receiving additional postremission therapy, and if an HLA-matched donor is available, based on the current available data, patients should be referred for this procedure as soon as possible.³³

Patients who do not have an HLA-matched sibling should receive intensive postremission chemotherapy using high-dose cytarabine or similar regimen. The optimal dose of high-dose cytarabine—anywhere from 1.5 g/m² to 3 g/m²—the optimal duration and the total number of doses have never been prospectively established. Only one retrospective analysis, combining several historic studies, suggested that three cycles of high-dose cytarabine are better than a single course.³⁴ While these are important practical questions affecting the manage-

ment of many patients with AML, there is little current enthusiasm among cooperative groups to study this prospectively in clinical trials.

There are multiple reports of autologous transplants for AML including many patients with intermediate cytogenetics. However, it is difficult to identify and analyze large cohorts of patients who have received this therapy. The MRC study reported a relapse rate of 35% for patients who have also received an autotransplant compared with 55% among patients receiving intensive chemotherapy only. The 5-year survival was 56% versus 48%.² It is generally assumed that those patients going on to an autologous transplant should receive prior intensive chemotherapy as the best method of *in vivo* purging. For such patients the intensity of postremission therapy as well as the number of cycles required are unknown and have also never been prospectively studied. Although some of the best results from phase II data of autologous transplants in AML have been reported when patients received no postremission therapy prior to the transplant,³⁴ the preponderance of the data suggest that using several cycles of postremission therapy should be given prior to transplant. Preliminary data have also reported that peripheral blood stem cells can be reliably collected after two cycles of intensive chemotherapy such as high-dose cytarabine with a subsequent very low transplant-related mortality rate.³⁵ Several cooperative groups are currently evaluating the role of gemtuzumab ozogamicin, a humanized monoclonal antibody against CD33 linked to calicheamicin, given in addition to high-dose cytarabine or prior to autologous transplant.

AML with unfavorable cytogenetics

This group has long been recognized to have the poorest outcome among patients with AML. While the initial response rate may exceed 50% (Table 3), the overall long-term survival remains poor, whatever mode of postremission therapy is employed. If a family-matched HLA donor is available, patients should be referred for this procedure as soon as possible after induction therapy. Although this probably represents current practice there aren't abundant prospective data that support this. The MRC AML 10 study reported that among the group with unfavorable cytogenetics allogeneic transplant did not offer any advantage.² However, there were only 13 patients in this group. In contrast, the US Intergroup study reported a clear advantage for patients undergoing an allogeneic transplant²⁷ with a 5-year survival of 44% compared to 15% for patients undergoing chemotherapy. However, once again, this was based on a very small subgroup of 18 patients using an intent-to-treat analysis and only 11 patients actually received this form of therapy. Nevertheless, this appears to represent a therapy with the greatest potential for prevention of relapse.

Because of the extremely high rate of relapse in this group of patients and the poor long-term outcome, it is important to note that select reports of alternative donors in this group of patients, which used either matched unrelated donors or haploidentically matched family donors, have shown long-term survival rates of 40-50% in patients undergoing such procedures in first remission.^{36,39} Whether such information on select patients can be applied to the group as a whole remains to be determined in clinical trials.

Bone Marrow Transplantation

Over the past decade a major effort was made to determine the role of bone marrow transplantation (BMT) in adult AML, especially autologous transplantation, compared to intensive chemotherapy. Several large prospective studies were designed and much effort was expended on these trials.^{9,24,26,29} The results have been confusing and the data difficult to interpret. It seems that a decade later this issue has still not been resolved. However, certain points need to be emphasized.

1. The preponderance of the data demonstrate that autologous transplants provide better antileukemic activity than intensive chemotherapy, as judged by the relapse rate (Table 5).
2. Historically, the superior antileukemic benefit of autotransplants was negated by the high procedural mortality of autologous transplants (14% in the US Intergroup study and 18% in the MRC AML 10 study). Were this mortality to be reduced by about 10% then the conclusions from these studies may be quite different. Current use of peripheral blood as a source of stem cells for autotransplants is associated with an extremely low procedural mortality.³⁵
3. All the major reported trials used bone marrow as the source of the stem cells and may not be relevant to current clinical practice in many centers. Aside from the higher procedural mortality, the morbidity when bone

Table 5. Relapse following allogeneic transplant, autologous transplant and chemotherapy.

| Study | Allogeneic transplant | Autologous transplant | Chemotherapy |
|-------------------------------|-----------------------|-----------------------|--------------|
| GIMEMA, 1995 ²⁹ | 24% | 40% | 57% |
| GOELAM, 1997 ²⁴ | 28% | 43% | 55% |
| *MRC, 1998 ²⁵ | 19% | 35% | 53% |
| ECOG/SWOG, 1998 ²⁸ | 29% | 48% | 61% |

* Data for children excluded. In the MRC study, BMT was compared with an observation arm after 4 cycles of chemotherapy, rather than a direct comparison with high-dose chemotherapy as in the other studies.

Abbreviations: See Table 3; GIMEMA, Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto

marrow is used is considerable with a median time to neutrophil recovery of approximately 25 days and over 7 weeks for platelet recovery. With such morbidity and mortality, using bone marrow, there had to be a vastly superior advantage to transplants for this to be considered a better option than chemotherapy.

4. However, most importantly, data from these studies are impossible to interpret due to the small number of patients analyzed per subgroup. The first disappointment was the very high dropout rate of patients, typical in all transplant studies. This dropout occurs at several stages. Only a proportion of patients eligible for randomization after induction actually go on to randomization. Also, a significant number of randomized patients never go on to receive the transplant. In the US Intergroup study approximately half of the patients who were randomized to an autotransplant never received one.²⁶ The validity of intent-to-treat analyses is uncertain when half of the patients do not receive their intended therapy. Furthermore, when these studies were designed over a decade ago AML was considered as a single entity and the number of patients for these studies was determined based on this consideration. With identification of the importance of prognostic groups, it became crucial to consider each of the prognostic subgroups. Once the data for these subgroups are broken down, the number in each patient group is extraordinarily small making any analysis difficult and potentially misleading. As an example, the US Intergroup study²⁶ accrued over 800 patients, and 116 were assigned to autologous transplant. However, only 63 (54%) of these 116 patients actually completed this therapy. These 63 patients were then divided into 3 subgroups: favorable, intermediate and unfavorable cytogenetics, leading to an analysis based on numbers that statisticians would never have agreed to had this been defined as the primary endpoint at the time of design of the study.²⁷ In fact, it has been estimated that in order to conduct such a study in AML patients and obtain meaningful results with data that could be reliably analyzed, an excess of 7,000 patients would be required. Thus, it is unlikely that such a study will ever be carried out which is the main reason why conflicting results from these transplant studies have been reported, especially when analyzed by subgroups. The most telling example of this may be gleaned from the analysis of the value of high-dose cytarabine in AML patients with favorable cytogenetics. The results from the CALGB studies report a disease-free survival in excess of 60%.²⁹ In contrast, the US Intergroup study reported that for this group of patients the 5-year survival was only 35%. This same study reported that when the identical therapy was applied to a group with less favorable cytogenetics—the intermediate group—the 5-year survival was 55%. These data, while providing some biologic information,

emphasize the pitfalls of drawing conclusions when small cohorts are involved and the inability to compare data between different studies.

Acute Myeloid Leukemia in Older Adults

Older adults have a dismal long-term prognosis that has not improved much over the past two decades (Figure 3). They have more unfavorable prognostic factors at presentation and their treatment is made more difficult by their inability to withstand intensive chemotherapy.⁴⁰ Further, the type of postremission therapy that they receive is generally considered to be sub-optimal even for the more favorable prognostic groups seen in younger adults. The critical factor is that a biologically unfavorable disease is treated sub-optimally.

Older adults who do not have significant comorbidities should be treated with standard induction therapy. With such therapy 50% of such patients can achieve a CR.^{41,42} The major difficulty relates to the selection of postremission therapy. Though patients can generally tolerate one cycle of cytarabine given at somewhat lower doses than is usually given for younger adults,⁴¹ it has never been shown that this improves the long-term outcome. This population represents the majority of individuals with AML, and major efforts are needed to determine the best therapy in this group of patients with the aim of achieving a possible cure in some patients and a prolongation of the disease-free survival in many others. Maintenance therapy has been studied in the past with some evidence that this can prolong the disease-free survival.⁴³ Current strategies aim to emphasize non-myeloablative immune modulation following induction and limited intensive post-remission therapy and include phase III studies evaluating the role of IL-2/histamine, IL-2 (CALGB) and Flt 3 ligand (ECOG/SWOG/CALGB). Future strategies to prolong the disease-free survival in older adults include proposed studies of gemtuzumab, ozogamicin, farnesyltransferase inhibitors and bcl-2 antisense oligonucleotides. Clearly, this is the area with the greatest challenge in AML: applying a less severely myeloablative form of postremission therapy that may, nevertheless, cure the most unfavorable prognostic type of the AML. Achieving this aim has so far been elusive. Such breakthroughs will, likely, also benefit younger adults.

II. MOLECULAR TARGETS IN ACUTE MYELOID LEUKEMIA

Jerald Radich, MD*

Acute myeloid leukemia (AML) is a heterogeneous disease characterized by a myriad of genetic defects. These include translocations involving oncogenes and transcrip-

tion factors, activation of signal transduction pathways, and alterations of growth factor receptors. If each type of genetic lesion found in AML involved a distinct process to cause leukemia, then "targeted" therapy directed at specific genetic lesions would be futile—quite simply, there would be too many potential targets. However, it appears that many of the pathways perturbed in leukemogenesis interact, so that a limited number of specific targets may be useful in a wide variety of AML cases. Indeed, if multiple genetic abnormalities are needed to cause and sustain AML, then the blunting of a single aberrant pathway may be enough to eliminate the proliferative advantage and curb the disease.

In this short review we will examine the signaling pathways involved in leukemogenesis, with specific emphasis as to how these pathways can be utilized as targets for novel therapy.

Normal Signal Transduction

Signal transduction pathways are designed to translate extracellular signals (e.g., stimulation to respond to cytokine ligands, interferons) into intracellular action (proliferation, differentiation, survival). Perhaps the best understood pathway involves signaling utilizing the *ras* family of guanine nucleotidases (GTPases). A highly simplified cartoon of the *ras* signal transduction pathway is shown in Figure 4 (see color page 541). The most important components include the following:

Receptor tyrosine kinase (RTK): These ligand binding receptors include PDGF, Fms, c-kit, and Flt 3.¹⁴ In general their structure includes an extracellular ligand binding region consisting of 5 immunoglobulin-like domains, transmembrane and juxta-membrane domains, and an intracellular domain with kinase activity (Figure 5; see color page 541).

Grb-2 and SOS: Grb-2 is an adaptor protein that functionally bridges the association of the RTK with *ras*. SOS is a guanine nucleotide exchange protein that facilitates *ras*-GDP→*ras*-GTP exchange.

Ras. Harvey (H), Kirsten (K), and N-*ras* are 21 kd GDP/GTP-binding proteins that serve as the hub of signal transduction.^{3,6} All three *ras* proteins are expressed in most tissues, but the constellation of muta-

tions (i.e., N-*ras* vs. K-*ras*) tend to be disease specific.

GAP, NF-1: These are GTPase activating proteins, that catalyze the inherently slow GTPase activity of *ras*, converting active *ras*-GTP to an inactive *ras*-GDP form.⁷

Briefly, extracellular ligand (L) interacts with the RTK that causes receptor dimerization (Figure 4). This prompts activation of the RTK and subsequent receptor autophosphorylation. This phosphorylated RTK can in turn phosphorylate and activate Grb-2, the adaptor protein, which when coupled to SOS, causes activation of the *ras*. Inactive *ras* remains bound with GDP, and the interaction with Grb2-SOS causes *ras* to become activated by GTP binding. This produces a conformational change in *ras*, and promotes interaction with downstream effector proteins. Since *ras* has an intrinsically slow GTPase activity, the switch back to the inactive *ras*-GDP state necessitates the activity of the GTPase-activating proteins (p210 GAP and NF-1).

Activation of *ras* causes activation of several downstream pathways, which may effect cell proliferation, differentiation, and apoptosis.^{8,12} The serine/threonine kinase Raf is activated by direct association with *ras*, and in turn activates the MAP/ERK kinase (MEK), which activates downstream mitogen-activating protein kinases (MAPK), such as extracellular signal-regulated kinases (ERK 1 and 2).¹³ These in turn phosphorylate cytoplasmic targets (Rsk, Mnk) that translocate to the nucleus, causing activation of transcription involved in proliferation. *Ras* activation also may influence cytoskeleton organization through activation of Rac and Rho. In addition, *ras* may promote cell cycling through the activation of Cyclin D dependent kinases (CDKs), by interacting alone, with Raf, or with Myc. Lastly, *ras* may play a part in inhibiting apoptosis. The activation of PI-3 kinase by *ras* activates c-Akt, which has been demonstrated to protect against apoptosis. Thus, *ras* pathways may take part in an extraordinary range of pathways regulating cell proliferation and death.

The initiation of the signal cascade takes place at the intracellular membrane, and thus *ras* must move from the cytoplasmic space to that site of action. For membrane association, *ras* proteins must undergo a post-translational modification called prenylation, which adds an isoprenoid moiety to the cytoplasmic *ras*.¹⁴ This prenylation is accomplished by the enzymes farnesyl and geranylgeranyl transferases, which add 15 and 17-mer isoprenoids, respectively, to the *ras* protein. Prevention of prenylation keeps *ras* in the cytoplasmic space and is the underlying rationale for therapy directed at the inhibition of farnesyl transferase.

The Janus kinase-signal transducer and activator of transcription (Jak/Stat) pathway is utilized by many

* Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D4-100, P.O. Box 19024, Seattle WA 98109-1024

Acknowledgments: I thank Drs. Derek Strewalt and Soheil Meshinchi for their helpful comments. In addition, because of size constraints of this review, important work from many colleagues had to be omitted. I apologize that I could not include all the contributions they have made to this field.

members of the cytokine receptor superfamily (erythropoietin, interferons, granulocyte colony stimulating factor [G-CSF]).^{15,16} These receptors, unlike the RTK noted above, lack their own intrinsic tyrosine kinase activity. Binding of ligand to receptor causes autophosphorylation of Jaks, and the activated Jaks in turn phosphorylate the receptor. These phosphorylated receptors are docking sites for signaling proteins, including Stats, which are in turn activated by phosphorylation. The activated Stats form dimers (either homodimers, or heterodimers with other Stats), translocate into the nucleus, and bind to specific DNA sequences, regulating gene transcription (Figure 4). There are at least 4 Jaks and 7 Stats, and the complex interaction between these regulate gene transcription in an elaborate fashion that is both gene and tissue specific. Further complexity arises in that Jaks and Stats may play a role in pathways not strictly in the Jaks/Stat pathway (e.g., Jak/STAT activation may occur through activation from the RTK/*ras*/MAPK pathway).

Abnormal Signal Transduction in AML

Perturbations in the signal transduction pathway are common in AML and occur through a variety of mechanisms. The precise cellular consequences of such inappropriate activation are unknown, but functionally it can be thought of as an uncontrolled activation of downstream targets causing inappropriate signals for proliferation and survival.

Tyrosine kinase receptor mutations

Mutations in the *Fms*, *Kit*, and *Flt3* RTKs have been described frequently in AML (Table 6). Activating point mutations in the kinase domains of *Fms* have been described in 5-10% of selected AML cases.¹⁷⁻¹⁹ Deletions, insertions, and point mutations have been found occasionally in the *Kit* receptor, often in cases with a mast-cell phenotype.^{20,21} However, mutations in the *Flt3* RTK appear quite common and may be the most common mutation so far discovered in AML.²²⁻²⁴

The *Flt3* receptor is preferentially expressed on hematopoietic stem cells and mediates stem cell differentiation and proliferation. *Flt3* receptor activation causes proliferation of AML cells in vitro, as it appears to both stimulate proliferation and inhibit apoptosis of the AML cells. Recently a unique mutation has been described in the *Flt3* gene, whereby a fragment of the JM domain-coding sequence (exons 11 and 12) is duplicated in direct head-to-tail orientation. This creates a so-called internal tandem duplication (ITD) mutation (Figure 5). The length of the ITD varies from approximately 20-200 base pairs and the duplicated sequence is always in-frame. In vitro studies have shown that mutant *Flt3*/ITD receptors are dimerized in a ligand-independent manner, leading to autophosphorylation of the receptor through consti-

tutive activation of the tyrosine kinase moieties, and leads to autonomous, cytokine independent growth in the mutant cells. Activation of signaling proceeds through the *ras*/MAPK and Stat 5 pathways.^{30,31}

Several studies have explored the prevalence and significance of the *Flt3*/ITD mutation. Common themes in these studies are that the mutation is associated with a pronounced leukocytosis, that the prevalence appears to increase with age, and that the presence of the *Flt3*/ITD may be associated with a poor prognosis, particularly in the pediatric population. The prevalence of the *Flt3*/ITD in two Japanese pediatric studies ranged from 5-11%, and was associated with a poor clinical outcome.^{23,24} More recently, analysis of 91 pediatric AML patients treated on a single Children's Cancer Group (CCG) study was performed and showed that 15 of 91 samples (16.5%) were positive for the *Flt3*/ITD.²⁵ None of the patients with the *Flt3*/ITD had unfavorable cytogenetic markers. Despite this, the remission induction rate was 40% in patients with the *Flt3*/ITD compared to 74% in patients without the *Flt3*/ITD, and event-free survival at 8 years was only 7% for those with the *Flt3*/ITD compared to 44% for patients without a mutation. The results in adult AML are not as conclusive in regards to *Flt3* and outcome. Two retrospective adult studies demonstrated that the presence of the *Flt3*/ITD was associated with poor outcome. Rombouts et al found *Flt3*/ITDs in 18/81 patients (22%), and found that the complete response rate (47% vs. 80%), relapse rates (75% vs. 26%), and leukemia-free survival rates (<10% vs. ~40%) were significantly poorer in patients with *Flt3* mutations compared to patients without mutations.³² Kiyoi found the *Flt3* mutation in 43/201 (22%) newly diagnosed AML cases but found no effect of the mutation on CR rates. However, survival among those with the *Flt3* mutation was inferior to those without the mutation (~20% vs. 50%).³⁴ On the other hand, a large study (N = 143) of "older" (> 55 years) AML cases from SWOG revealed that the presence of *Flt3*/ITD did not have an adverse effect on outcomes.²⁷ However, in this elderly AML group, response and outcome was universally (and predictably) poor in all genetic subgroups. This study found a very high rate of *Flt3*/ITD in 34% of cases, thus fortifying the association of increasing *Flt3* with increasing age.

Table 6. RTK mutations in acute myeloid leukemia.

| Gene | Mutation | Prevalence | Refs. |
|------|-------------------------------------|------------|--------|
| Flt3 | Internal tandem duplication | 15-30% | 39-49 |
| | Point mutation | 5-10% | 51 |
| Fms | Point mutation | 10-20% | 35, 36 |
| Kit | Point mutation, deletion, insertion | <10% | 37, 38 |

American Society of Hematology

Point mutations in the Flt3 activation loop have recently been described in 7% of adult AML patients.²⁴ Curiously these point mutations were not associated with leukocytosis, unlike Flt3/ITDs, although those having a point mutation shared an equally poor event-free survival as those with the Flt3/ITD compared to patients without the mutation. While Flt3/ITD activation seems to work through ERK and Stat5 pathways, it is unknown if the point mutations behave in the same fashion.

ras mutations

Mutations in N-, K-, or H- *ras* occur in approximately 10-30% of AML cases (Table 7).³³⁻⁴⁰ They also occur in myelodysplastic syndrome (MDS) (~5-20%),^{17,41} juvenile CML (20-30%),^{42,43} and CMML (30-50%).^{17,44} *Ras* mutations occur rarely in blast phase CML.^{44,45} In leukemia (as opposed to solid tumors), mutations are predominately in N-*ras*, less commonly in K-*ras*, and quite infrequently in H-*ras*. These mutations are point mutations in codons 12, 13, and 61, with rare exceptions,⁴⁶ and act to prevent the hydrolysis of ras-GTP; effectively, this causes the activated ras to be constitutively stuck in the "on" position. Intuitively this activation would likely lead to constitutive activation of downstream pathways normally controlled by *ras*, but this may not entirely be the case. For example, in a study of primary AML cases, fully one-half had constitutive activation of ERK, but none of these cases had *ras* mutations. In addition, mutated *ras* has been found in vitro to bypass some of the normal signal transduction intermediaries and bind directly with the transcription activator, JunB.

NF-1 mutations

Children with neurofibromatosis have an increased incidence of juvenile CML (JCML), often associated with a mutation in the NF-1 gene. The structure and function of NF-1 is similar to GAP, so that a decrease in its activity promotes the maintenance of the ras-GTP state, presumably inappropriately activating the transduction pathway.^{47,48} N-*ras* mutations also occur often in patients with JCML, but only in those with normal NF-1.^{49,50} GAP mutations in other myeloid leukemias are rare.⁵¹

Table 7. *Ras* mutations in myeloid leukemia.

| Disease | Prevalence | Refs. |
|-----------------------------------|------------|--------|
| Acute myeloid leukemia | 15-30% | 22-27 |
| Myelodysplastic syndrome | 5-30% * | 28, 29 |
| Juvenile chronic myeloid leukemia | 20-30% ** | 30, 31 |
| Chronic myeloid leukemia | Rare | 32, 33 |

*Perhaps depending on phase of disease.

** If wild type NF-1.

Aberrant activation of the Jak/Stat pathway

The most direct example of aberrant activation of Jak/Stat are from translocations that either directly involve genes or directly activate the pathway. For example, the t(9;12) translocation involving Tel-Jak2 has been found in both lymphocytic and myeloid leukemia.^{52,53} This translocation contains the helix-loop-helix oligomerization domain of Tel and the catalytic domain of Jak2. Dimerization promotes the activation of Jak, which in turn leads to constitutive activation of the downstream Stat 5. Similar activation of Stat 5 occurs from the inappropriate kinase activity of Bcr-Abl. In addition, inappropriate activation of Stats 1 and 3 have been found in primary acute leukemia cells. For example, mutations in the RTK Flt3 appear to activate Stat 5, whereas activating mutations in c-kit appear to activate Stat 3 and (to a lesser degree) Stat 1.⁵⁴

Translocations

Translocations have been described that activate the *ras* pathway directly. For example, in CML specific domains on the BCR moiety of the chimeric BCR-ABL protein interact with the docking protein Grb-2, which then couples with SOS to activate ras. In CMML, the t(5;12) translocation involves the Tel gene and the β chain of PDGFR.⁵⁵ The Tel dimerization causes autophosphorylation of PDGFR, which activates ras via an interaction with Grb-2/SOS. In addition, the central role of ras activation in CMML is underlined by the frequent mutation in N-*ras* in those patients without the t(5;12) translocation.

Summary

Taken together, aberrations in signal transduction pathways appear to be quite common in AML. In fact, two studies have measured the frequency of *ras* and Flt3 mutations in a single population and found that just these two genes account for 30-50% of patients with mutations involving the RTK/*ras* pathway. Analysis of Kit and Fms receptors might increase the prevalence even further. Thus, drugs designed to target this pathway, particularly at downstream "choke points," might be effective in a surprisingly large number of AML cases.

New Drugs Aimed at Molecular Targets

To reiterate, mutations in the *ras*-mediated signal transduction pathway are present in 30-50% of AML by direct mutational analysis. Indeed, approximately 50% of AML cases at diagnosis have abnormal phosphorylation of ERK, indicative of inappropriate pathway activation. Targeted therapy could be leveraged at many fronts.

Rationale for RTK inhibition

As noted above, mutations in RTKs are a common abnormality in AML. The exciting success of the tyrosine

kinase inhibitor (TKI) STI571 in CML has caused a flurry of activity toward developing TKIs directed at aberrant RTK function.^{56,57} Unfortunately, while STI571 inhibits Bcr-Abl, Abl, and PDGF, it has limited activity on Flt3 or Fms;⁵⁸ however, it has substantial activity against c-kit and may be effective in the small subset of leukemia patients harboring that mutation. In c-kit mutant cell lines, the addition of STI571 inhibits Kit autophosphorylation and effectively blocks activation of ERK and Akt.⁵⁹ Inhibition of Flt3 in mouse and human leukemia cells can be accomplished with the TKIs herbimycin A and AG1296, which inhibit mutant Flt3 autophosphorylation as well as abrogate *in vitro* growth independence of Flt3/TTD cell lines.⁵⁹

Treatment with the novel tyrosine kinase inhibitor SU5416 has recently been described in an AML patient in refractory second relapse.⁶⁰ SU5416 blocks the activity both vascular endothelial growth factor receptor 2 (VEGFR-2) and the stem cell factor (SCF) receptor c-kit. The patient treated had evidence by flow cytometry of blasts that expressed both VEGFR-2 and c-kit. SU5416 monotherapy was instituted and by 12 weeks a CR was achieved. This CR was durable for an additional 6 months on maintenance SU5416 therapy alone. Analysis of the bone marrow microenvironment revealed a decrease in microvessel density suggesting a decline in angiogenesis caused by VEGFR-2 activity. The report is the first documented durable remission induced with specific RTK inhibition in AML.

Ras inhibition

Farnesyltransferase inhibitors (FTI) target the post-translational modification of *ras* to prevent subcellular localization necessary for participation in signal transduction. The first phase I trial of a FTI inhibitor in hematological malignancies has recently been completed in 35 adults with refractory and relapsed acute leukemias.⁶¹ The non-peptidomimetic FTI inhibitor R115777 was given at doses from 100 mg b.i.d. to 1200 mg b.i.d. for up to 21 days. Dose-limiting neurotoxicity was encountered at 1200 mg b.i.d. The overall response rate in 25 AML patients was 32% (8/25, with 6 partial and 2 complete responses). Biochemical assays showed that the FTI activity was inhibited by a dose of 600 mg b.i.d., and at this level clinical responses were seen in 2/7 (29%) AML patients, suggesting that this may be a reasonable drug level for future phase 2 trials. Activation of the MAPK pathway was found in 8 patients, and in 4 this activity was curbed after R115777 treatment. It is unclear if the patients with ERK response were the same that revealed clinical responses. Curiously, none of the 25 AML patients had evidence of N-*ras* mutations; RTK mutations were not evaluated. However, 3/5 patients with monosomy 7, a defect that may be associated with aberrant *ras* expres-

sion, had a clinical response, implicating some activity against *ras* activity. How, then, is R115777 working in the bulk of these patients? Other effectors of *ras* activation, such as RhoB, and members of the PI3/AKT-2 pathway, need farnesylation for activity, and perhaps these downstream effectors represent more crucial targets for FT inhibition.^{62,63}

There may be other targets for *ras* inhibition, based on its necessary physical interactions with downstream effectors. X-ray crystal structures of normal and oncogenic *ras* have been determined, and crucial binding sites of SOS, GAP, and Raf have been defined.^{51,57} These are rational targets for small molecules designed to block these areas of protein-protein interaction. Moreover, elucidation of the conformational changes that occur in the mutant *ras* protein structure may provide structural targets for therapy. Lastly, the finding that mutated *ras* binds Jun, perhaps bypassing normal *ras* signaling pathways, offers a potential target that would maintain normal *ras* function.

Rationale for Jak/Stat inhibitors

Activation of the Jak/Stat pathway appears common in AML, especially involving Stats 3 and 5. Inhibiting activation of Stat could be accomplished at the receptor level (by blocking ligand binding or inactivating RTK activity), by blocking Stat phosphorylation and subsequent dimerization, by small molecule interactions with the SH2 domain, or by small molecules targeting Stat consensus DNA binding domains.⁶⁴ In addition, oligonucleotide therapy has been directed at inhibiting Stat expression.⁶⁵ These novel approaches are currently in the pre-clinical phase of development.

The Discovery of New Molecular Targets

The study of the molecular biology of leukemia has been limited by the painstaking process of gene identification and the difficulty of unraveling the complicated networks that drive normal (and abnormal) cellular function. However, the payoff of the Human Genome Project and the advances in micro-engineering and informatics has ushered in an area of genetic research where it is possible to study > 10,000 genes simultaneously by use of mRNA expression arrays. While this technology is in its infancy, it has already been demonstrated that it may be a powerful tool for finding new biological classification methods in leukemia and lymphoma. For example, the work of Golub et al suggests that gene arrays can be used to determine a set of genes that distinguish ALL from AML, and holds considerable promise towards a molecular classification of cancer.⁶⁶ As a model approach, the study demonstrated the feasibility of molecular classification and described a general strategy for discovering new classification schemes independent of previous knowl-

edge or biases. Such technology may also be used to study pathways as well. Experimental studies have been successfully performed in yeast, where pathways have been mapped by using controlled manipulations of variables followed by mRNA expression analysis.⁶⁷ This has elucidated considerable, unanticipated "cross-talk" between several MAPK mediated pathways, such as those regulating filamentous growth and mating responses. Similar approaches can be imagined in human cancers. Unanticipated and unique pathways might be uncovered in leukemia cells that are quite different than normal pathways. The effects of potential drugs on various pathways can be assessed, and interactions discovered that would likely never be apparent with conventional methodology.

Conclusion

Leukemia cells bypass normal control of growth, differentiation, and apoptosis. However, in skirting these normal checks and balances, they place themselves in the tenuous position of relying on aberrant cellular mechanisms for survival. For example, if the activation of the ras pathway causes both inappropriate proliferation and a block in apoptosis, the inactivation of the pathway may both decrease the proliferation drive, as well as relieve the check of programmed death. The results with ST1571 have shown how ungoverned signal transduction can be used as "pharmaceutical judo" to control disease when the aberrant signal is suddenly blocked. Further characterization of signaling pathways in AML, partnered with novel drug development, promises a new approach to the treatment of leukemia.

III. IMMUNOLOGIC APPROACHES TO THE TREATMENT OF ACUTE MYELOID LEUKEMIA

*Frederick R. Appelbaum, MD**

The creation of an effective immunologic approach to the treatment of acute myeloid leukemia (AML) has been a goal of many researchers over the past two decades. Finally, with the development of gemtuzumab ozogamicin (Mylotarg), there is one example of a therapy based at least in part on an immunologic approach that has won FDA approval for the treatment of AML. Recent advances in immunology give us hope that this example will be neither the last nor the best. This brief article offers a review of preclinical and clinical work currently underway in the field.

* Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D5-310, P.O. Box 19024, Seattle WA 98109-1024

Antibody-Based Approaches to AML

Unconjugated monoclonal antibodies

Unconjugated monoclonal antibodies can kill tumor cells in one of three general ways. They can induce fatal immunologic injury via complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC). They can react with cell receptors resulting in signal transduction events that directly lead to apoptosis without a significant contribution from CDC or ADCC. And finally, they can, at least theoretically, block the binding of other factors necessary for cell survival.

The only unconjugated antibodies systematically studied in AML target the CD33 antigen. CD33 is a glycoprotein found on blasts from more than 90% of cases of AML. It is expressed on almost all normal early myeloid and erythroid progenitors but is not on normal hematopoietic stem cells or nonhematopoietic tissue. Although the normal function of CD33 is not known, it is thought to be a member of the Siglec family with immunoreceptor tyrosine-based inhibitory motifs in its cytoplasmic domain. There is no evidence that ligation of CD33 induces apoptosis; thus, use of unconjugated antibody therapy in AML directed at CD33 is thought to depend on the antibody's ability to inflict immunologic injury on the tumor cell.

Initial studies of murine anti-CD33 antibodies showed that the antibody could be administered with relatively little toxicity other than fever and chills, that there was rapid uptake of antibody in marrow and spleen, and that antigenic sites on leukemic and normal cells were saturated with antibody doses of 5-10 mg/m².^{1,2} While transient drops in circulating blast counts occurred in some patients, no sustained responses were seen, demonstrating that the murine antibody was incapable of initiating an effective immunologic response.

In an effort to increase immunologic potency, the Sloan-Kettering group developed a chimeric humanized form of one anti-CD33 antibody, termed HuM195. In a phase II trial of this agent in 35 patients, transient drops in peripheral blast counts were seen, and one patient with less than 30% blasts at the start of treatment achieved a complete remission.³ Attempts to augment the immunologic reactivity of HuM195 by combining it with IL-2 did not lead to a marked increase in clinical activity.⁴

Given the relative lack of activity in overt AML, subsequent trials of unconjugated HuM195 have been conducted in patients in clinical remission. In one study, patients with acute promyelocytic leukemia (APL) in remission following treatment with chemotherapy and retinoic acid were given 3 mg/m² HuM195 twice weekly for six doses. Of 27 patients in first remission, 22 had evidence of minimal residual disease by reverse transcription PCR assay for PML/RAR α rearrangements. Of

these 22, 11 became PCR negative after antibody therapy.⁵ Current trials are examining HuM195 in combination with retinoic acid and arsenic trioxide in APL and in combination with conventional chemotherapy for patients with AML in first relapse.

Drug conjugates and immunotoxins

Although unconjugated antibodies to CD33 do not have major clinical activity in overt AML, the antibodies are capable of reaching sites of leukemia, saturating the antigenic sites on leukemic cells and internalizing after cell surface binding. These observations together with the fact that CD33 is absent from the surface of the normal hematopoietic stem cell and all non-hematopoietic sites suggested that antibodies to CD33 might serve as an effective vehicle to target potent drug conjugates to leukemic cells while sparing the normal hematopoietic stem cell and normal organs.

Working with investigators from Lederle Laboratories, the Seattle group developed the drug immun-conjugate Mylotarg, which joins a humanized anti-CD33 IgG4 antibody to the potent antitumor antibiotic calicheamicin. Mylotarg was initially evaluated in a phase I dose escalation trial involving 40 patients with refractory or relapsed AML.⁶ Patients received 0.25-9 mg/m²/dose q14 days for up to 3 doses. Dose escalation was stopped at 9 mg/m² because at that dose more than 90% of antigenic sites on leukemic cells were saturated. The most common side effects were fever, chills, transient transaminasemia and the expected myelosuppression. Peripheral blast counts dropped in virtually all patients receiving doses of 6 mg/m² or more of drug. When all dose levels were considered, 8 of 40 patients (20%) had complete clearance of bone marrow blasts, 3 of whom had full hematopoietic recovery.

The combined results of three multicenter phase II trials of Mylotarg have recently been reported.⁷ In these studies, 142 patients with AML in first relapse were treated with 9 mg/m² of Mylotarg on days 1 and 14. Most patients experienced the post-infusion syndrome of fever, chills and hypotension, but this usually cleared by 8 hours. Grade 3-4 mucositis (4%), nausea and vomiting (11%) and serious documented infections (28%) were less frequent than seen with most aggressive reinduction regimens. Grade 3-4 elevation in transaminases was seen in 17% of patients and was usually transient, although one of the 142 patients died of apparent veno-occlusive disease of the liver. Overall, 30% of patients achieved remission, defined as less than 5% blasts in marrow and recovery of red cell and neutrophil counts to normal and platelet transfusion independence. Of these 30, 11 had not recovered to 100,000 platelets prior to receiving subsequent post-reinduction therapy. Based on its activity

and favorable safety profile, Mylotarg was approved by the FDA for the treatment of CD33 positive AML in first relapse in patients 60 years and older who are not good candidates for aggressive reinduction regimens.

An analysis of leukemic blasts from 126 of the 142 patients treated on the phase II Mylotarg studies described above found that increased surface expression of P-glycoprotein (Pgp) and increased Pgp function, as demonstrated by cyclosporine (CSA) inhibitable dye efflux, correlated with treatment failure.⁸ Specifically, 52% of samples from patients who failed to achieve remission exhibited dye efflux compared to only 24% of those from patients who achieved remission. Similarly, apoptosis induced by in vitro exposure to Mylotarg was reduced in blasts with high levels of Pgp expression and in those from patients who failed to achieve remission. Addition of cyclosporine to cultures containing Mylotarg significantly increased apoptosis in approximately 1/3 of such cases.

Current trials of Mylotarg include the use of the agent as de novo treatment in older individuals, in combination with cytarabine or cytarabine plus an anthracycline, as a debulking agent prior to nonablative transplantation, as maintenance therapy in younger patients in remission, and in combination with cyclosporine.

As an alternative to targeting CD33, Frankel et al have developed a fusion protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) combined with diphtheria toxin as a means to specifically target myeloid cells. An early report of a phase I dose escalation trial reported on 26 patients with relapsed or refractory AML.⁹ Frequently seen toxicities were generally limited to fever and chills, and in 3 of the 26 patients greater than 90% reduction in marrow blasts was seen.

Radioimmunoconjugates

Radioimmunoconjugates have been investigated as therapy for AML both as a stand-alone treatment and in the context of hematopoietic cell transplantation. Because leukemia cells are adjacent to normal hematopoietic stem cells, the only real hope of delivering adequate doses of radiotherapy to the tumor cell without also irradiating normal stem cells would be with a radionuclide possessing an extremely short path length, such as an alpha emitter like ²¹³Bi. The Sloan-Kettering group has explored a ²¹³Bi-HuM195 conjugate in a dose escalation trial.¹⁰ Seventeen patients with recurrent AML were treated with HuM195 conjugated to 0.28-1 mCi/kg ²¹³Bi and, although blasts decreased in numbers in 12 of 17, no complete responses occurred and pancytopenia was significant at the higher dose levels.

Given the obvious concern that radionuclides targeted to leukemic cells would irradiate adjacent normal stem cells, most trials of antibody targeted radiotherapy

for AML have now been conducted in the context of hematopoietic cell transplantation. To date, three different targets have been explored: CD33, CD45 and CD66. The rationale for these studies comes, in part, from prior randomized trials attempting to identify an optimal dose of total body radiation (TBI) included in transplant preparative regimens. In these studies, it was found that increasing the dose of TBI from 12 to 15.75 Gy significantly reduced the risk of post-transplant relapse but was associated with an increase in non-relapse mortality.^{11,12} If, by using radioimmunoconjugates, the dose of radiation to sites of leukemia could be similarly increased without affecting normal tissues such as the liver, lung and gastrointestinal mucosa, then cure rates might be significantly improved.

An initial trial in Seattle involved the use of ¹³¹I-labeled anti-CD33 in 9 patients with recurrent AML.² The trial design involved first administering a trace-labeled dose of the antibody to determine biodistribution and, if more radiation was predicted to be delivered to the marrow, spleen and other known sites of leukemia than to normal organs (a finding termed "favorable biodistribution"), treating patients on a dose escalation trial by adding increasing doses of ¹³¹I-labeled anti-CD33 to a standard 120 mg/kg cyclophosphamide (CY) plus 12 Gy TBI regimen. Although rapid uptake of the trace-labeled antibody in the marrow and spleen was seen, the residence time of the radionuclide was very short, due to antigen-antibody internalization and dehalogenation, and in only 4 of 9 patients was "favorable" biodistribution found.

Jurcic et al from Sloan-Kettering have explored a similar approach, adding ¹³¹I-M195 (120-230 mCi/m²) in 2-4 divided doses to a standard busulfan (BU) 16 mg/kg plus CY 120 mg/kg preparative regimen.¹³ They report that among 19 patients all engrafted, and no unexpected toxicities were seen. However, because of the short retention of the radionuclide in the marrow, this approach required multiple infusions of the radionuclide to achieve the desired marrow dose, which led to prolongation of the preparative regimen and the peri-transplant neutropenic phase. Given this experience, the Sloan-Kettering group is now exploring the use of ⁹⁰Y-HuM195, a radioimmunoconjugate that they hypothesize should reside longer in marrow and leukemic sites. An initial phase I trial appears to support this hypothesis.¹⁴ Their group is now exploring ⁹⁰Y-HuM195 plus etoposide as a stem cell transplant preparative regimen.

CD45 has been explored as an alternative target for radioimmunotherapy in AML. It is expressed by most hematopoietic cells, save mature red cells and platelets, and is not expressed by non-hematopoietic cells. Compared to CD33, it is found in far higher copy numbers per cell and does not internalize upon antibody binding.

Preclinical studies in mice and macaques showed that ¹³¹I-labeled anti-CD45 antibodies could deliver higher doses of radiation to spleen (13-fold) and marrow (3- to 4-fold) than to any normal organ.^{15,16}

Given these data, Matthews and the Seattle group conducted a phase I trial in which patients with recurrent acute leukemia were given a trace-labeled dose of an ¹³¹I-labeled murine anti-CD45 antibody (BC8) following which biodistribution studies were conducted.¹⁷ If favorable biodistribution was found, patients went on to receive increasing doses of ¹³¹I conjugated to BC8 combined with CY (120 mg/kg) plus 12 Gy TBI followed by marrow transplantation. Among 44 patients, favorable biodistribution was found in 84%, with marrow and spleen receiving 6-13 cGy/mCi as opposed to 2.8, 1.8 and 0.6 delivered to liver, lungs and total body. Mucositis became dose limiting at doses above 10.5 Gy delivered to normal organs. This, in turn, meant that it was possible to administer approximately 20 Gy of marrow via the radioimmunoconjugate in addition to the standard CY plus TBI regimen. Approximately 30% of patients treated on this study became long-term survivors, but given patient heterogeneity, no conclusions about possible impact of the added radioimmunotherapy on outcome are possible.

A phase II trial of ¹³¹I-BC8 combined with standard dose BU (16 mg/kg) plus CY (120 mg/kg) as a preparative regimen for patients with AML with first remission is ongoing.¹⁸ The dose of ¹³¹I-BC8 is calculated to deliver 5.25 Gy to liver, or approximately 12 Gy and 29 Gy to marrow and spleen. Among 40 patients so far treated, relapse rates have been low (15%), grade 3-4 toxicity acceptable, and 70% of patients are calculated to be alive, disease-free, at 5 years.

CD66 is present on maturing hematopoietic cells but not on leukemic blasts. However, by targeting CD66, it should be possible to deliver radiation to leukemic cells as innocent bystanders. Bunjes et al have been exploring the use of ⁸⁸Re-anti-CD66 as an adjunct to a standard preparative regimen and report that they can deliver approximately 15 Gy to marrow in addition to a standard preparative regimen.¹⁹ Among 36 patients with myeloid malignancies, 58% are alive in remission 17 months after treatment with this approach.

Cellular-Based Approaches to AML

Allogeneic hematopoietic cell transplantation

Although the existence of a graft-versus-leukemia (GVL) effect has been recognized since it was first described by Barnes et al in 1956,²⁰ only in the last few years have investigators begun to focus on allogeneic HSCT as a potential immunotherapeutic approach rather than primarily as a vehicle for delivering high dose therapy.²¹

Three general observations have led to this change in focus. First, studies have consistently found that after allogeneic HSCT, relapse rates are least in patients who develop both acute and chronic graft-versus-host disease (GVHD), higher in those who develop no clinically evident GVHD, and higher still if T cells are depleted from the marrow graft.²² A second observation emphasizing the potential power of GVL comes from the results of treating patients for post transplant relapse by infusing viable donor lymphocytes. Complete sustained responses have been reported in substantial proportions of patients including up to 75% of patients with CML in chronic phase and 30% of patients with AML.²³ A final set of observations that have dramatically increased interest in the GVL effect show that allogeneic engraftment can be achieved following administration of preparative regimens that are not truly myeloablative. For example, the M.D. Anderson group has been exploring the use of purine analogs (2-CDA or fludarabine) combined with various combinations of melphalan, idarubicin, or cytarabine to treat older or debilitated patients with myeloid malignancies.²⁴ Slavin et al and the group from Jerusalem have explored the use of fludarabine combined with antithymocyte globulin and busulfan (8 mg/kg) as a preparative regimen with reduced intensity.²⁵ Storb and the Seattle group have shown that if intensive post-transplant immunosuppression is given, including cyclosporine and mycophenolate mofetil, sustained engraftment can be obtained in virtually all recipients of transplants from matched siblings following a preparative regimen consisting only of fludarabine 90 mg/m² and 200 cGy TBI.²⁶ While each of these approaches has its own unique potential advantages and drawbacks, they all support several consistent conclusions. First, sustained complete engraftment of allogeneic stem cells can be achieved with non-myeloablative preparative regimens. Second, such transplants are associated with considerably less toxicity than traditional transplant approaches. For example, among the first 100 patients treated on the Seattle regimen, with a median age of 53, the 100-day transplant-related mortality was 4.5%. Third, substantial numbers of patients with active disease at the time of transplant have achieved complete remission and, although the follow-up is still short, most patients transplanted while in remission have remained in remission. However, the numbers of patients in any one study are still quite limited and follow-up is still too brief to allow for definitive conclusions about the efficacy of this approach. Nonetheless, the potential power of the GVL effect coupled with the ability to achieve allogeneic engraftment without the toxicities associated with very high dose therapy has generated increased interest in transplantation as an immunotherapeutic approach.

While it is critically important to define the clinical utility of existing non-myeloablative transplant approaches for the treatment of AML, the procedure, as currently applied, is still accompanied by a substantial incidence of GVHD. Further, it is unlikely that the anti-leukemic effects of non-myeloablative approaches will be greater than seen with conventional transplantation and likely will turn out to be less. Thus, methods to augment the GVL effect without causing GVHD are needed.

Polymorphic minor histocompatibility antigens as targets for GVL

One approach to segregating the anti-tumor from anti-host reactions following allogeneic HSCT has been to identify polymorphic minor histocompatibility antigens with expression largely limited to hematopoietic tissues. Such antigens might serve as useful targets for post-transplant donor derived T cell therapy that should, in principle, be capable of eradicating host normal and malignant hematopoietic tissue. A number of minor histocompatibility antigens fulfilling this description have been identified by the groups from Leiden and Seattle.^{27,28} Studies have now been initiated in which donor derived T cells recognizing such antigens are isolated, expanded, and then used post-transplant in those settings where non-specific DLI infusions have previously been used.²⁹

Non-allogeneic targets for cellular therapy

Use of polymorphic minor histocompatibility antigens as a means of segregating GVL from GVHD, while rational, will always require the setting of allogeneic HCT for application. Thus, attempts have been made to identify non-allogeneic peptides associated with the malignant phenotype that then might be used as candidate antigens for both allogeneic and autologous T cell therapy or possibly as peptide vaccines. The two categories of antigens that have been studied so far are mutational, such as BCR-abl and DEK-can, and overexpressed self-antigens, including PR3 and WT1.

BCR-abl encodes a fusion-product protein not expressed by normal cells, which thus could serve as a tumor-specific peptide, at least in CML, some cases of ALL and rare cases of AML. In vitro studies have found that peptides derived from BCR-abl protein can elicit autologous T cell responses that are class I restricted. A phase I clinical trial has evaluated a vaccine consisting of 4 peptides able to bind to HLA class I. The vaccine was studied in 12 patients with CML, 3 at each of 4 dose levels.³⁰ Two of the 12 patients developed a possible delayed type hypersensitivity reaction to the vaccine following therapy and 3 showed proliferative responses when T cells were cultured with the peptides. However, no cytotoxic T cell responses could be detected.

A second fusion protein under study is the DEK-

can protein derived from the (6;9) translocation sometimes seen in AML. In one study, a CD4-positive T cell line was shown able to kill an autologous B cell line pulsed with peptides derived from the fusion protein.³¹

Two non-mutated proteins highly overexpressed in AML cells have been the focus of a number of recent studies. PR3 is a neutral serine protease with expression largely restricted to the promyelocytic stage of myeloid differentiation. It is expressed by leukemic progenitors from patient with AML and CML but is minimally expressed by normal marrow progenitors. CD8-positive T cells specific for PR3 have been generated that can selectively lyse leukemic blasts but not normal bone marrow cells. Further, CD8-positive cytotoxic T cells specific for PR1, a peptide derived from PR3, were able to be isolated from the peripheral blood of patients with CML in remission after allogeneic transplantation or interferon.³² Based on these findings, a vaccine based on the PR1 peptide is now being evaluated in a phase I trial.

WT1 is a zinc finger transcription factor, abundantly overexpressed by most human leukemias including AML, CML and ALL. T cells can be generated that recognize WT1 peptides and lyse leukemic CD34-positive cells but not normal CD34-positive cells and inhibit growth of leukemic, but not normal, myeloid colonies.³³ Antibodies to WT1 have been detected in the serum of some patients with AML suggesting, as in the case of PR3, that an active immune response to the antigen is not necessarily associated with obvious toxicities, making it a candidate for an adoptive T cell or vaccine strategy.

Whole cell vaccine strategies

An alternative to identifying specific antigens to use as targets for T cell clones or as vaccines is, instead, to vaccinate with genetically altered autologous tumor cells. Previous studies demonstrated that mice vaccinated with syngeneic tumors engineered to secrete GM-CSF develop particularly potent immune responses.³⁴ Accordingly, studies have been conducted in murine models of AML testing the utility of AML cells transduced to secrete GM-CSF and found that such vaccines can improve cure rates in mice with established tumors treated with chemotherapy.³⁵ Similarly, a vaccine composed of AML cells transduced with the gene for IL-12 has been found to have high activity in a similar murine model.³⁶ Other studies have suggested that immune responses can be further enhanced by performing such vaccinations after autologous transplantation, perhaps because the transplant eliminates an inhibitory effect of the intact immune system.³⁷

A related approach to the development of whole cell vaccines has been to culture peripheral blood mononuclear cells of leukemic patients with cytokines, including GM-CSF and IL-4, in an effort to induce the leuk-

mic cells to assume characteristics of dendritic cells. These cells should theoretically become much more immunogenic and thus could serve as tumor vaccines.³⁸

IV. MODELING HUMAN LEUKEMIA IN VIVO

*John E. Dick, PhD**

Our understanding of the leukemogenic disease process has, to a large extent, been formed from many decades of research on human subjects involving characterization of the cellular phenotype of acute leukemia and other aspects of the clinical picture. One of the major difficulties with this approach is the limited ability for experimental intervention in human subjects. Moreover, it is almost impossible to gain insight into the early events of the leukemogenic process before they become clinically apparent. Until the last decade, most experimental approaches have involved the study of naturally occurring animal (mostly murine) leukemia and experimentally induced disease following transgenic or gene knock-out methods. However, while many aspects of these murine leukemias recapitulate the human disease, there can be significant differences with the human disease. For example, some translocations that cause lymphoid diseases in humans (e.g. E2A-PBX, HOX 11) result in myeloid disease when expressed in mice. Moreover, marked differences in genomic stability between humans and inbred mice strains suggest that the leukemogenic process might be subtly different. Ultimately, one would like to complement murine experiments with model systems that utilize human leukemia to ensure that they are relevant to the human situation and that therapies based on this knowledge will have a higher likelihood of efficacy in humans. The transplantation of normal and leukemic human cells into immune-deficient mice provides such a system. This review will examine progress in using this xenograft model to characterize the leukemic clone, with particular emphasis on the identification of the leukemic stem cell in AML, and to develop novel therapeutic strategies.

Heterogeneity of Normal Human Stem Cells

The mammalian hematopoietic system is a hierarchy derived from stem cells that possess extensive self-re-

* Program in Cancer/Blood Research, The Hospital for Sick Children, 555 University Avenue, Toronto ONT M5G 1X8, Canada

Acknowledgments: Supported by grants from the Canadian Institutes for Health Research (CIHR), the National Cancer Institute of Canada (NCIC) with funds from the Canadian Cancer Society, the Canadian Genetic Disease Network of the National Centers of Excellence, and a CIHR Scientist award.

newal, proliferative, and differentiative capacity. Hematopoietic stem cells maintain the hematopoietic system throughout life, and stem cell regulation is a critical element in the control of normal hematopoiesis. The stem cell developmental program is tightly regulated by a combination of intrinsic factors as well as external stimuli such as soluble cytokines and contact with stroma. Disregulation of this tightly controlled developmental program as a consequence of aberrant expression of oncogenes results in leukemic proliferation. Thus, understanding the cellular and molecular factors that regulate the developmental program of normal stem cells and those that initiate proliferative diseases such as leukemia remains one of the major challenges in biology.

Hematopoietic stem cells possess extensive proliferation, differentiation, and self-renewal potential; properties that can only be conclusively examined by *in vivo* repopulation. The composition of the human hematopoietic stem cell compartment is poorly understood because of the historic absence of experimental tools to characterize the developmental program of individual stem cells. We have used repopulation of immune-deficient BNX, SCID and NOD/SCID mice to develop a quantitative assay for human stem cells that have been termed SCID-repopulating cells (SRC).¹⁻⁴ The key property that defines SRC is the potential for repopulation of multiple hematopoietic lineages. This system closely models conventional methods of human bone marrow transplantation and murine reconstitution assays of stem cell function. A detailed characterization of SRC is emerging in terms of frequency, cell surface phenotype, and cytokine responsiveness.⁵⁻¹¹ However, it is not known if the SRC assay detects a functionally homogeneous population of stem cells or if, like the murine system, there is heterogeneity in the reconstitution potential of

individual stem cells. The recent discovery of Lin-negative CD34-negative CD38-negative SRC and sheep-repopulating cells that appear to be precursors of the more numerous SRC from the Lin-negative CD34-positive CD38-negative fraction suggest phenotypic heterogeneity might exist in the human stem cell compartment.^{12,13}

To understand the composition of the human hematopoietic stem cell compartment, we have tracked the *in vivo* fate of individual SRC during repopulation of NOD/SCID mice by analysis of the unique clonal markers that were introduced with retroviral vectors.¹⁴ The vector integration site provides a marker that is stably inherited by all progeny of an active stem cell. Analysis of serial bone marrow aspirations from NOD/SCID mice transplanted with transduced cord blood demonstrated that the repopulation was oligoclonal with extensive variability in self-renewal capacity as well as in the lifespan and proliferative capacity of individual SRC. Some clones only contributed for several weeks after the transplant and disappeared, while others appeared later and persisted. Secondary repopulation experiments demonstrated that there was heterogeneity in the self-renewal capacity of the transduced SRC. These data point to the existence of different classes of human stem cells with short- and long-term-repopulating capacity (ST- and LT-SRC, respectively) (Figure 6).

Using NK cell-deficient, $\beta 2$ -microglobulin^{negative}/NOD-SCID mice, Glimm et al have found that short-term human repopulation can occur within the first several weeks following transplantation of Lin-negative CD34-positive CD38-positive cells.¹⁵ Unlike SRC, many of these short-term repopulating cells (STRC) were restricted to the myeloid lineage. Furthermore, Lin-negative CD34-positive CD38-positive cells cannot engraft NOD/SCID mice, pointing to a fundamental difference between STRC and SRC, which possess lympho-myeloid differentiation capacity. However, lin-negative CD34-positive CD38-positive cells can engraft short-term NOD-SCID mice treated with anti-NK antibodies, similar to the $\beta 2$ -microglobulin^{negative}/NOD-SCID mice.¹⁴ Taken together with the findings of Guenechea et al,¹⁴ these findings provide convincing evidence that the stem cell compartment, as assayed by repopulation, is heterogeneous in terms of cell surface phenotype as well as in functional properties (Fig. 6).

Acute Myeloid Leukemia

AML, an impaired differentiation program results in the excess production of leukemic blasts, of which the vast majority have limited proliferative capacity.¹⁶ Therefore, the leukemic clone must be maintained by rare sub-




Figure 6. Heterogeneity of transplantable stem cells from Glimm et al¹⁴ and Guenechea et al.¹⁴

Long-term and short-term SCID-repopulating cells (LT-SRC and ST-SRC, respectively) are detected in NOD/SCID mice and generate another class of short-term repopulating cell (STRC) that can only be assayed in the NK cell deficient $\beta 2$ -microglobulin knock-out/NOD-SCID mouse or in anti-NK treated NOD/SCID mice. The STRC can generate either myelo-lymphoid cells (STRC-ML) or are restricted to either lineage, STRC-M or STRC-L.

populations of leukemic stem cells with extensive proliferative and self-renewal capacity.^{17,18} Thus, identification of AML stem cells is central to understanding the leukemogenic process, and their elimination is the only real target for effective therapy. The blasts from different patients are heterogeneous in their differentiation stage. The mechanism underlying this heterogeneity is unknown, as is the nature of the leukemic stem cells. Further, the identity of the target cell that undergoes leukemic transformation in AML has been controversial. Two major hypotheses have been put forward to explain heterogeneity in AML (reviewed in ^{4,19}). One model (Figure 7; see color page 542) suggests that many different cell types in the stem/progenitor hierarchy are susceptible to transformation.^{17,20} The level of commitment of the target cell influences the characteristics of the resulting leukemic blast cells. This model predicts that the phenotype of the leukemic stem cells from patients with myelomonocytic blasts, for example, would be different from the leukemic stem cells from patients whose blasts expressed few lineage markers. The second model (Figure 8; see color page 542) suggests that critical mutations/translocations responsible for transformation and progression exert a leukemogenic effect only in HSC.^{18,21} The leukemic clone that arises is organized as a hierarchy with a leukemic stem cell generating clonogenic progenitors and leukemic blasts. According to this model, heterogeneity results from the variable ability of these primitive leukemic stem cells to differentiate or acquire lineage markers, depending upon the repertoire and direct influence of specific transformation or progression-related gene(s) and not on the degree of commitment of the target cell. This model predicts little variability in the phenotype of the leukemic stem cells among different patients. Another consequence of the initial transforming event(s) would be impairment of differentiation to other lineages (e.g. erythroid or lymphoid) emanating from the pluripotential stem cell target.

Xenotransplant Assay for

Acute Myeloid Leukemia Stem Cells

Initial attempts to develop animal models for human leukemia involved subcutaneous transplantation of patient samples or leukemic cell lines into nude mice. This method created myelosarcomas or localized solid tumors, neither of which is characteristic of the disease. SCID-leukemia and NOD/SCID-leukemia models have been developed using the same paradigm as described above for normal human hematopoiesis. Leukemic cell transplantation successfully engrafts these mice and faithfully recapitulates the pathology of the original human leukemia. These systems have been applied to the study of most human leukemias, including AML, ALL, CML, and ICML (reviewed in ⁴).

Identification of the AML stem cell, based upon initiation of AML in immune-deficient mice (termed the SCID-Leukemia initiating cell, SL-IC), provides insight into the organization of the cells that comprise the leukemic clone and a means to rationally develop novel therapies directly targeted to the stem cell.^{21,22} SL-IC were found in the primitive CD34++CD38- fraction (similar to normal HSC) of AML blood regardless of the differentiation stage or FAB subtype of the leukemic blasts suggesting that the initial transformation events occur in HSC consistent with the model outlined in Figure 3. Moreover, we conclusively showed that the AML clone was organized as a hierarchy that is maintained by stem cells that undergo leukemic differentiation. Stem cells within the highly purified CD34-positive CD38-negative cell fraction from AML samples could differentiate, albeit abnormally, to generate a leukemic cell phenotype identical to the donor. Moreover, the dissemination characteristics of either M4/M5 samples (widespread to non-hematopoietic tissues) or M1 (limited to hematopoietic tissues) was reproduced, suggesting that the SL-IC assay can be used to study this mechanism.^{21,22} Limiting dilution assays showed that the frequency of SL-IC ranged from 0.2-100/10⁶, while serial transplantation into secondary mice showed that the SL-IC possessed extensive self-renewal capacity, a key determinant of stem cells. It remains to be seen whether the SL-IC frequency correlates with patient response or outcome. Recent studies on a large number of AML samples found that secondary AML or primary AML that fail to respond to therapy engraft more extensively in NOD/SCID mice compared to primary samples.²³ Moreover the most significant correlate to high level engraftment was WBC count of the donor sample, suggesting that the overall proliferative capacity of the SL-IC may vary greatly. Since the ability to detect an SL-IC depends on its proliferative capacity within the murine microenvironment, variance in frequency of SL-IC observed between patients may reflect proliferative capacity more than a true measure of actual stem cell frequency.²³ Nevertheless, this quantitative assay enables the monitoring of patients undergoing drug therapy, cytokine therapy, purging, and BM transplantation by examining the effect of these treatments on leukemic stem cells.

Phenotype of SL-IC

While initial studies demonstrated phenotypic similarity between normal and leukemic stem cells, subtle differences in the cell surface phenotype that might be exploited clinically have recently been discovered. For example, SL-IC have been found within the CD34-positive Thy-1-negative and CD34-positive CD71-negative HLA-DR-negative sub-population, in contrast to normal HSC.^{24,25} Strikingly, the SL-IC appear to uniquely ex-

press IL-3 receptor α chain (CD123) while normal stem cells do not appear to express this marker.²⁶ The biological significance of this result is not clear since this receptor does not appear to signal through the common pathways associated with this receptor. Expression of c-kit is usually associated with normal stem cells; however, transplantation studies showed that only CD34-positive/c-kit-negative cells contained SL-IC.²⁷ Again, the biological significance is not clear since the cells were able to respond to the c-kit ligand, SCF, suggesting that undetectable levels might still be present. Nevertheless, the surface expression of this receptor is clearly different between normal and leukemic stem cells. All of these studies provide new reagents to characterize the leukemic stem cell and suggest purification strategies for future purging experiments.

The significant enrichment of SL-IC makes possible a detailed analysis of the biology of these elusive cells. Progress along these lines is beginning. Gene expression analysis of highly purified normal and AML-derived CD34-positive CD38-negative cells has revealed a number of interesting conserved genes that were not expected to be expressed in neoplastic cells including the tumor-suppressor genes, interferon regulatory factor 1 (IRF-1) and death associated protein kinase (DAPK). These data are surprising in that pro-apoptotic factors are typically absent from malignant cells, indicating that IRF-1 and DAPK may play a role in the biology of early leukemogenic cells.⁴⁵ Future studies need to focus on identification of the full expression profile of leukemic stem cells as compared with normal stem cells.

The discovery of CD34-negative HSC^{12,13} in normal hematopoietic tissues raises the possibility that this cell might also be a target of AML transformation and that SL-IC with this phenotype might exist. Conversely, these stem cells might not be the target for leukemic transformation and therefore represent a pool of normal stem cells that might be exploited clinically. A very small number of patients have been found to contain both CD34-negative and CD34-positive SL-IC,²⁸ but it is not known if leukemic progression-related changes deregulated CD34 expression or if this reflects the existence of a primitive target cell. Recent studies using normal mouse hematopoietic cells have identified stem cells based on their efflux of Hoechst 33342 (termed side population or SP-positive).²⁹ In the mouse, they are largely CD34(negative) and enriched for primitive progenitors and stem cells. Characterization of AML samples has revealed the existence of SP-positive CD34-negative cells that are part of the leukemic clone and have SL-IC activity.^{30,46} However, additional subfractionation has found that the SP-positive CD34-positive CD38-negative cells have SRC activity and are non-leu-

kemic.³⁰ These early studies point the way to interesting areas for future research both for leukemic stem cell biology and for their potential to identify differences between normal and leukemic stem cells that might be exploited clinically.

APL (FAB M3) may be a distinct entity and represent a real exception to the stem cell model. It appears that the leukemic stem cell in APL may not be derived from the primitive hematopoietic compartment because the PML-RAR α fusion gene was present only in the CD34-positive CD38-positive population.³¹ Interestingly, APL cells do not appear to engraft SCID or NOD/SCID mice, supporting this idea.^{21,22} Thus, transformation at the level of committed myeloid progenitors (or STRC as illustrated Figure 6) may be the exception rather than the rule.

Therapeutic Strategies

The availability of a model that faithfully reproduces the human disease in mice provides a powerful tool to develop and test new approaches to AML treatment. There is little question that effective treatment must eliminate the AML stem cell or relapse will occur. A large literature is developing on the use of SCID and NOD/SCID leukemia models to test new therapies. I will only focus on several selected examples here. The first key element of these approaches is the use of primary AML samples rather than cell lines that might have acquired alterations during establishment of the cell line that are not reflective of the original donor. The second element is the use of the model in such a way as to point to killing of the leukemic stem cell.

The efficacy of allogeneic HSCT as a curative therapy for acute and chronic leukemia depends both on the intensive chemoradiotherapy administered prior to transplant and a GVL effect mediated by donor T cells. However, a significant fraction of patients with advanced leukemia at the time of HSCT will relapse due to persistence of leukemic progenitor cells. Escalation of the doses of chemoradiotherapy has not improved survival due to increased toxicity and efforts to augment the GVL effect after transplant such as by the administration of unselected donor lymphocytes or the administration of interleukin-2 were only partially effective, and/or complicated by increased GVHD.^{32,33} Adoptive T cell immunotherapy targeting human minor histocompatibility (H) antigens expressed in recipient hematopoietic cells but not in nonhematopoietic cells such as skin fibroblasts and keratinocytes has been proposed as one strategy for inducing a GVL effect without causing GVHD.^{34,35} CD8-positive CTL clones specific for minor H antigens have been demonstrated to lyse a proportion of myeloid and lymphoid leukemic cells in vitro and inhibit the growth of clonogenic myeloid leukemic progenitor cells in me-

thylcellulose culture.³⁷⁻³⁹ These CD8-positive CTL clones inhibit the engraftment of human AML cells in NOD/SCID mice following short-term incubation with AML cells prior to transplant into NOD/SCID mice.⁴⁰ The inhibition was mediated by direct CTL recognition of SL-ICs. These results implicate CD8-positive minor H antigen-specific CTL as mediators of the GVL effect associated with allogeneic HSCT, and provide an experimental model to identify and select T cell clones for immunotherapy to prevent or treat relapse after allogeneic HSCT.

Other approaches have involved the development of immunotoxins that target toxic molecules to the leukemic stem cell. Several groups have focused on the diphtheria toxin/GM-CSF receptor immunotoxin.^{41,42} These studies have indicated that the SL-IC expresses the GM-CSF molecule since SL-IC were specifically killed by treating the AML cells with these molecules.

Conclusions

Leukemic stem cells hold the key to understanding origin and maintenance of AML and for developing effective therapy. In the future, comparison of the gene expression profiles of highly purified fractions of normal and leukemic stem cell fractions should provide the basis for identification of leukemia-specific patterns of gene expression. It will be possible to determine the biological function of these newly discovered genes in terms of their ability to interfere with the normal developmental program of normal human stem cells, using experimental models where leukemia-associated oncogenes are expressed in primary human hematopoietic cells using retroviral vectors.⁴³ Together, these approaches should identify novel targets for leukemic therapy, which can, in turn, be tested in vivo using the NOD/SCID-leukemia system.

REFERENCES

I. Current Standard Therapy of Adult AML

1. Paietta E, Andersen J, Raczek J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. *Leukemia*. 1994;8:968-973.
2. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. *Blood*. 1998;92:2322-2333.
3. Marty M, Ganem G, Fisher J, et al. Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin. *Nouv Rev Fr Hematol*. 1984;26:731-738.
4. Avvisati G, Pini M, Coco FL. Event-free survival duration in newly diagnosed acute promyelocytic leukemia is favorably influenced by induction treatment with idarubicin alone: Final results of the GIMEMA randomized study (LAP 389) comparing IDA versus IDA+ARA-C in newly diagnosed APL. *Blood*. 1999;94:2259a.
5. Head D, Kopecky K, Wicks J, et al. Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Southwest Oncology Group. *Blood*. 1995;86:1717-1728.
6. Estey E, Tall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. *J Clin Oncol*. 1997;15:483-490.
7. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. *N Engl J Med*. 1997;337:1021-1028.
8. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all-trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. *Blood*. 1999;94:1192-1200.
9. Burnett AK, Grimwade D, Solomon E, Wheatly K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of Randomized MRC Trial. *Blood*. 1999;93:4131-4143.
10. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR-alpha-positive acute promyelocytic leukemia. PETHEMA group. *Blood*. 1999;94:3015-3021.
11. Fenaux P, Chevret S, Guerci A, et al. Long term follow-up confirms the benefits of all-trans retinoic acid in acute promyelocytic leukemia. *Leukemia*. 2000;14:1371-1377.
12. Lengfelder E, Reichert A, Schoch C, et al. Double induction strategy including high-dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. *Leukemia*. 2000;14:1362-1370.
13. Asou N, Adachi K, Tamura J, et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. *J Clin Oncol*. 1998;16:78-85.
14. Rowe JM. Uncertainties in the standard care of acute myelogenous leukemia. *Leukemia*. 2001;15:677-679.
15. Meloni G, Diwario D, Vignetti M, et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pre-transplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR α fusion in gene. *Blood*. 1997;90:1321-1325.
16. Dillman RO, Davis RB, Green MR, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. *Blood*. 1991;78:2520-2526.
17. Wiernik PH, Banks PL, Case DC, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. *Blood*. 1992;79:313-319.
18. Berman B, Arlin ZA, Gaynor J, et al. Comparative trial of cytarabine and thioguanine in combination with ansacrine or daunorubicin in patients with untreated acute nonmyelophocytic leukemia: results of the L-16M protocol. *Leukemia*. 1989;3:115-121.
19. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish National Phase III Trial. The Danish Society of Hematology Study Group Leukemia on AML, Denmark. *Leukemia*. 1991;5:510-516.
20. Arlin ZA, Case DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin

- in previously untreated patients with acute nonlymphoblastic leukemia (ANLL). *Leukemia*. 1990;4:177-183.
21. Bishop JF, Matthews JP, Young GA. A randomized trial of high-dose cytarabine in induction in acute myeloid leukemia. *Blood*. 1996; 87:1710-1717.
 22. Rowe JM, Tallman MS. Intensifying induction therapy in acute myeloid leukemia: Has a new standard of care emerged? *Blood*. 1997; 90:2121-2126.
 23. Preisler HD, Early A, Raza A, et al. Therapy of secondary acute nonlymphocytic leukemia with cytarabine. *N Engl J Med*. 1983;308: 21-24.
 24. Harousseau JL, Cahn JY, Pignon B, et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. *Blood*. 1997;90:2978-2986.
 25. Burnett AK, Goldstone AH, Stevens RMF, et al. Randomised comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. *Lancet*. 1998;351:700-708.
 26. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. *N Engl J Med*. 1998;339:1649-1656.
 27. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. *Blood*. 2000;96:4075-4083.
 28. Ziuoun RA, Mandelli F, Willenize R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. *N Engl J Med*. 1995;332:217-223.
 29. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. *J Clin Oncol*. 1999;17:3767-3775.
 30. Storb R. Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia? *Leukemia*. 2001;15:662-663.
 31. Appelbaum FR, Dahlborg S, Thomas ED, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia: a prospective comparison. *Ann Intern Med*. 1984;101:581-588.
 32. Hewlett J, Kopecky KJ, Head D, et al. A prospective evaluation of the roles of allogeneic marrow transplantation and low-dose monthly maintenance chemotherapy in the treatment of adult acute myelogenous leukemia (AML): A Southwest Oncology Group study. *Leukemia*. 1995;9:562-569.
 33. Tallman MS, Rowlings PA, Milone G, et al. Effect of postremission chemotherapy prior to HLA-identical HLA-identical sibling transplantation for acute myelogenous leukemia in first complete remission. *Blood*. 2000;96:1254-1258.
 34. Cassileth PA, Andersen J, Lazarus HM, et al. Autologous bone marrow transplant in acute myeloid leukemia in first remission. *J Clin Oncol*. 1993;11:314-319.
 35. Cassileth PA, Lee SJ, Miller KB, et al. Feasibility study of adding high-dose cytarabine in induction and consolidation before autologous stem cell transplant in adult acute myeloid leukemia. *Blood*. 1998;92(suppl. 1):4559a.
 36. Sierra J, Supper B, Hansen JA, et al. Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience. *Bone Marrow Transplant*. 2000;26:397-404.
 37. Rowe JM, Lazarus HM. Genetically haploidentical stem cell transplantation for acute leukemia. *Bone Marrow Transplant*. 2001;27: 669-676.
 38. Aversa F, Velardi A, Tibilio A, et al. Haploidentical stem cell transplantation in leukemia. *Blood Rev*. 2001;15 111-119.
 39. Anasetti C. Transplantation of hematopoietic stem cells from alternate donors in acute myelogenous leukemia. *Leukemia*. 2000;15:502-504.
 40. Rowley JD, Alimena G, Garson OM, et al. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient's age and karyotype. *Blood*. 1982;59:1013-1032.
 41. Rowe JM, Andersen JW, Mazza JJ, et al. Randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55-70 years of age) with acute myelogenous leukemia: a study of Eastern Cooperative Oncology Group (E1490). *Blood*. 1995;86:457-462.
 42. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. *Cancer and Leukemia Group B. N Engl J Med*. 1995;332:1671-1677.
 43. Buchner T, Urbanitz D, Hiddemann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. *J Clin Oncol*. 1985;3:1583-1589.

II. Molecular Targets in AML

1. Rösner O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. *Oncogene*. 1991;6:1641-50.
2. Lyman SD, James L, Zappone J, Sleath PR, Beckmann MP, Bird T. Characterization of the protein encoded by the flt3 (flt2) receptor-like tyrosine kinase gene. *Oncogene*. 1993;8:815-22.
3. Sherr CJ, Rettenmier CW, Sacca R, Roussel MF, Look AT, Stanley ER. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. *Cell*. 1985;41:665-76.
4. Broudy VC. Stem cell factor and hematopoiesis. *Blood*. 1997;90:1345-64.
5. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. *Nature*. 1993;366:643-654.
6. Bos JL. Ras oncogenes in human cancer: a review. *Cancer Res*. 1989;49:4682-4689.
7. Balaster R, Marchuk D, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. *Cell*. 1990;63:851-9.
8. Kang CD, Do IR, Kim KW, et al. Role of Ras/RK-dependent pathway in the erythroid differentiation of K562 cells. *Exp Mol Med*. 1999;31:76-82.
9. Katz ME, McCormick F. Signal transduction from multiple Ras effectors. *Curr Opin Genet Dev*. 1997;7:75-9.
10. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myo-induced apoptosis by R is signalling through PI(3)K and PKB. *Nature*. 1997;385:544-8.
11. Khosravi-Far R, White MA, et al. Oncogenic Ras activation of Raf/kinogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. *Mol Cell Biol*. 1996;16:3923-33.
12. Kishida S, Koyama S, Matsubara K, Kishida M, Matsura Y, Kikuchi A. Colocalization of Ras and Raf on the membrane is required for Ras-dependent Raf activation through Raf GDP dissociation stimulator. *Oncogene*. 1997;15:2899-907.
13. Moodie SA, Wolfman A. The 3Rs of life: Ras, Raf, and growth regulation. *Trends in Genet*. 1994;10:44-48.
14. Gelb MH. Protein prenylation, et cetera: signal transduction in two dimensions. *Science*. 1997;275:1750-1.
15. Taniguchi T. Cytokine signalling through non-receptor protein tyrosine kinases. *Science*. 1995;268:251-5.

16. Ihle JN. Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells. *Adv Cancer Res.* 1996;68:23-65.
17. Padua RA, Guinn B-A, Al-Sabah A, et al. *Ras*, *FMS*, and *p53* mutations and poor clinical outcome in myelodysplasias: a 10 year follow-up. *Leukemia.* 1998;12:887-892.
18. Ridge SA, Worwood M, Osler D, Jacobs A, Padua RA. *FMS* mutations in myelodysplastic, leukemic, and normal subjects. *Proc Natl Acad Sci U S A.* 1990;87:1377-80.
19. Tobai K, Pagliuca A, Bhatt B, Bailey N, Layton DM, Mufti GJ. Mutation of the human *FMS* gene (*M-CSP* receptor) in myelodysplastic syndromes and acute myeloid leukemia. *Leukemia.* 1990;4:486-9.
20. Gari M, Goodeve A, Wilson G, et al. *c-kit* proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukemia. *Br J Haematol.* 1999;105:894-900.
21. Speer WR, Walchhofer S, Horny HP, et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the *c-kit* mutation Asp-816 to Val. *Br J Haematol.* 1998;103:740-9.
22. Kiyoi H, Naoe T, Yokota S, et al. Internal tandem duplication of *FLT3* associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohselsho). *Leukemia.* 1997;11:1447-52.
23. Iwai T, Yokota S, Nakao M, et al. Internal tandem duplication of the *FLT3* gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. *Leukemia.* 1999;13:38-43.
24. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of *FLT3* and *N-RAS* gene mutations in acute myeloid leukemia. *Blood.* 1999;93:3074-80.
25. Xu F, Taki T, Yang HW, et al. Tandem duplication of the *FLT3* gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. *Br J Haematol.* 1999;105:155-62.
26. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the *FLT3* gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. *Leukemia.* 1997;11:1605-9.
27. Stürwalt DL, Kopecky KJ, Meshinchi S, et al. *FLT3*, *RAS*, and *TP53* mutations in elderly patients with acute myeloid leukemia. *Blood.* 2001;97:3589-95.
28. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the *flt3* gene found in acute myeloid leukemia. *Leukemia.* 1996;10:1911-8.
29. Meshinchi S, Woods WG, Stürwalt DL, et al. Prevalence and prognostic significance of *FLT3* internal tandem duplication in pediatric acute myeloid leukemia. *Blood.* 2001;97:89-94.
30. Mizuki M, Fenski R, Halfter H, et al. *Flt3* mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the *Ras* and *STAT5* pathways. *Blood.* 2000;96:3907-14.
31. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated *Flt3* constitutively activates *STAT5* and *MAP* kinase and introduces autonomous cell growth in IL-3-dependent cell lines. *Oncogene.* 2000;19:624-31.
32. Kondo M, Horibe K, Takahashi Y, et al. Prognostic value of internal tandem duplication of the *FLT3* gene in childhood acute myelogenous leukemia. *Med Pediatr Oncol.* 1999;33:525-9.
33. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the *Flt3* gene [In Process Citation]. *Leukemia.* 2000;14:675-83.
34. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of *FLT3* in human hematologic malignancies. *Blood.* 2001;97:2434-9.
35. Farr CJ, Saiki RK, Erlich HA, McCormick J, Marshall CJ. Analysis of *RAS* gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. *Proc Natl Acad Sci U S A.* 1988;85:1629-33.
36. Burtram CR, Ludwig WD, Hiddemann W, et al. Acute myeloid leukemia: analysis of *ras* gene mutations and clonality defined by polymorphic X-linked loci. *Leukemia.* 1989;3:247-56.
37. Radich JP, Kopecky KJ, Willman CL, et al. *N-ras* mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. *Blood.* 1990;76:801-807.
38. Bos JL, Verlaan-de Vries M, van der Eb AJ, et al. Mutations in *N-ras* predominate in acute myeloid leukemia. *Blood.* 1987;69:1237-41.
39. Janssen JW, Steenvoorden AC, Lyons J, et al. *RAS* gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. *Proc Natl Acad Sci U S A.* 1987;84:9228-32.
40. Vogelstein B, Civin CI, Preisinger AC, et al. *RAS* gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study. *Genes Chromosomes Cancer.* 1990;2:159-62.
41. Paquette RL, Landaw EM, Pierre RV, et al. *N-ras* mutations are associated with poor prognosis and increased risk of leukemia in myelodysplasia syndrome. *Blood.* 1993;82:590-599.
42. Miyauchi J, Asada M, Sasaki M, Tsunomaru Y, Kojima S, Mizutani S. Mutations of the *N-ras* gene in juvenile chronic myelogenous leukemia. *Blood.* 1994;83:248-54.
43. Flotho C, Valcamonica S, Mach-Pascual S, et al. *RAS* mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). *Leukemia.* 1999;13:32-7.
44. Hirsch-Ginsberg C, LeMaistre AC, Kantarjian H, et al. *RAS* mutations are rare events in Philadelphia chromosome-negative/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia. *Blood.* 1990;76:1214-9.
45. Collins SJ, Howard M, Andrews DF, Agura E, Radich J. Rare occurrence of *N-ras* point mutations in Philadelphia chromosome positive chronic myeloid leukemia. *Blood.* 1989;73:1028-32.
46. Byrnie JL, Marshall CJ. The molecular pathophysiology of myeloid leukaemias: *Ras* revisited. *Br J Haematol.* 1998;100:256-64.
47. Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. *Cell.* 1990;62:599-608.
48. Xu GF, Lin B, Tanaka K, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates *ras* GTPase and complements *ira* mutants of *S. cerevisiae*. *Cell.* 1990;63:835-41.
49. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal *NF1* allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. *N Engl J Med.* 1994;330:597-601.
50. Bollag G, Clapp DW, Shih S, et al. Loss of *NF1* results in activation of the *Ras* signaling pathway and leads to aberrant growth in hematopoietic cells. *Nat Genet.* 1996;12:144-8.
51. Preudhomme C, Vachec A, Quesnel B, Wamé E, Cosson A, Fenaux P. Rare occurrence of mutations of the *FLR* exon of the neurofibromatosis 1 (*NF1*) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) [letter]. *Leukemia.* 1993;7:1071.
52. Peeters P, Raynaud SD, Cools J, et al. Fusion of *TEL*, the *ETS*-variant gene 6 (*ETV6*), to the receptor-associated kinase *JAK2* as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. *Blood.* 1997;90:2535-40.
53. Lacomique V, Boureux A, Valle VD, et al. A *TEL*-*JAK2* fusion protein with constitutive kinase activity in human leukemia.

- Science. 1997;278:1309-12.
54. Ning ZQ, Li J, Arceti RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. *Blood*. 2001;97:3559-67.
 55. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGFR receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. *Cell*. 1994;77:307-16.
 56. Pat EF, Krengel U, Pecsko GA, Goody RS, Kabsch W, Wittinghofer A. Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 Å resolution: implications for the mechanism of GTP hydrolysis. *Embo J*. 9:2351-9, 1990
 57. Monaco R, Chen JM, Chung D, Brandt-Rauf P, Pincus MR. Comparison of the computed three-dimensional structures of oncogenic forms (bound to GDP) of the ras-gene-encoded p21 protein with the structure of the normal (non-transforming) wild-type protein. *J Protein Chem*. 1995;14:457-66.
 58. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. *J Clin Invest*. 2000;105:3-7.
 59. Zhao M, Kiyoi H, Yamamoto Y, et al. In vivo treatment of mutant FLI3-transformed murine leukemia with a tyrosine kinase inhibitor. *Leukemia*. 2000;14:374-8.
 60. Mesters RM, Padro T, Bicker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. *Blood*. 2001;98:241-3.
 61. Karp JE, Lanct JB, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical-laboratory correlative trial. *Blood*. 2001;97:3361-9.
 62. Yuan ZQ, Sun M, Feldman RI, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. *Oncogene*. 2000;19:2324-30.
 63. Lebowitz PF, Prindergast GC. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. *Oncogene*. 1998;17:1439-45.
 64. Frank DA. STAT signaling in the pathogenesis and treatment of cancer. *Mol Med*. 1999;5:432-56.
 65. Marra F, Choudhury GG, Abboud HE. Interferon-gamma-mediated activation of STAT1alpha regulates growth factor-induced mitogenesis. *J Clin Invest*. 1996;98:1218-30.
 66. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science*. 1999;286:531-7.
 67. Roberts CJ, Nelson B, Marton MJ, et al. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles. *Science*. 2000;287:873-80.
 4. Kossman SE, Scheinberg DA, Jurcic JG, Jimenez J, Caron PC. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia. *Clin Cancer Res*. 1999; 5:2748-2755.
 5. Jurcic JG, DeBlasio T, Dumont L, Yao TJ, Scheinberg DA. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. *Clin Cancer Res*. 2000;6:372-380.
 6. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 (allicheamycin immunoconjugate). *Blood*. 1999;93:3678-3684.
 7. Sievers EL, Larson RA, Stedmauer BA, et al. Efficacy and safety of Mylotarg™ (Gemtuzumab Ozogamicin) in patients with CD33-positive acute myeloid leukemia in first relapse. *J Clin Oncol*. In press.
 8. Linenberger ML, Hong T, Flowers D, et al. Multidrug resistance phenotype and clinical responses to Mylotarg™ (Gemtuzumab Ozogamicin). *Blood*. In press.
 9. Mone AP, Howard DB, Molnar I, Kreitman RJ, Rankel AE. Resistant acute myeloid leukemia responds to a novel diphtheria toxin/GM-CSF fusion protein: summary of an ongoing phase I trial [abstract]. *Blood*. 2000;96 (Part 1):117a, #504.
 10. Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. *J Nucl Med*. 1999;40:1935-1946.
 11. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. *Blood*. 1990;76:1867-1871.
 12. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens. *Blood*. 1991;77:1660-1661.
 13. Jurcic JG, Caron PC, Nikula TK, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. *Cancer Res*. 1995;55:5908a-5910s.
 14. Jurcic JG, Divgi CR, McDevitt MR, et al. Potential for myeloablation with yttrium-90-HuM 195 (anti-CD33) in myeloid leukemia [abstract]. *Proc Am Soc Clin Oncol*. 2000;19:8a, #24.
 15. Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. *Cancer Res*. 1992;52:1228-1234.
 16. Matthews DC, Appelbaum FR, Eary JF, et al. Radiolabeled Anti-CD45 monoclonal antibodies target lymphohematopoietic tissue in the macaque. *Blood*. 1991;78:1864-1874.
 17. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of ¹³¹I-Anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. *Blood*. 1999;94:1237-1247.
 18. Ruffner KL, Matthews DC. Current uses of monoclonal antibodies in the treatment of acute leukemia (Review). *Semin Oncol*. 2000;27:531-539.
 19. Bunjes DW, Buchmann I, Duncker C, et al. Using radiolabeled monoclonal antibodies to intensify the conditioning regimen for patients with high-risk AML and MDS: a single centre experience of 36 transplants [abstract]. *Blood*. 2000;96 (Part 1):386a, #1667.
 20. Barnes DWH, Corp MJ, Loutit JP, Neal FE. Treatment of murine leukaemia with x-rays and homologous bone marrow. Preliminary communication. *Br Med J*. 1956;1:626-627.
 21. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. *Nature*. In press.
 22. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. *Blood*.

- 1990;75:555-562.
23. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. *Blood*. 1995;86:2041-2050.
 24. Giral S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. *Blood*. 1997;89:4531-4536.
 25. Slavin S, Nagler A, Nappashtek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. *Blood*. 1998;91:756-763.
 26. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. *Blood*. 2001;97:3390-3400.
 27. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy (Review). *Immunol Rev*. 1997;157:125-140.
 28. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. *Blood*. 1998;91:2197-2207.
 29. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. *Blood*. 1999;93:2336-2341.
 30. Pinilla-Ibarz J, Cathcart K, Korontsis T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. *Blood*. 2000;95:1781-1787.
 31. Ohnishi H, Yasukawa M, Kaneko S, et al. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DBK-CAN fusion peptide. *Blood*. 1999;93:925-935.
 32. Mollnes JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. *Nat Med*. 2000; 6:1018-1023.
 33. Gao L, Bellantoni L, Elsäßer A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. *Blood*. 2000;95:2198-2203.
 34. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. *Proc Natl Acad Sci USA*. 1993;90:3539-3543.
 35. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bizer BE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. *Blood*. 1998;91:222-230.
 36. Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. *Blood*. 1999;94:4263-4273.
 37. Bonnell I, Sommayor EM, Rattis F-M, Cooke SK, Gu L, Levitsky HL. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. *Blood*. 2000;95:3011-3019.
 38. Cignetti A, Bryant E, Allione B, Vime A, Foa R, Cheever MA. CD34+ acute myeloid and lymphoid leukemic blasts can be

induced to differentiate into dendritic cells. *Blood*. 1999;94:2048-2055.

IV. Modeling Human Leukemia in Vivo

1. Kamel-Reid S, Dick JE. Engraftment of immune-deficient mice with human hematopoietic stem cells. *Science*. 1988;242:1706-1709.
2. Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE, Dick JE. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in *scid* mice. *Science*. 1992;255:1137-1141.
3. Larochelle A, Vormoor J, Hanenberg H, et al. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. *Nature Med*. 1996;2:1329-1337.
4. Wang JC, Dorrell C, Ito CY, et al. Normal and leukemic human stem cells assayed in immune-deficient mice. In Zon LI, ed. *Hematopoiesis: A Developmental Approach*. New York: Oxford University Press; 2001:99-118.
5. Wang JC, Doedens M, Dick JE. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. *Blood*. 1997;89:3919-3924.
6. Bhatia M, Bonnet D, Kapp U, Wang JC, Murdoch B, Dick JE. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture. *J Exp Med*. 1997;186:619-624.
7. Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. *Proc Natl Acad Sci USA*. 1997;94:5320-5325.
8. Connolly E, Cashman J, Petzer A, Barnes C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. *Proc Natl Acad Sci U S A*. 1997;94:9836-9841.
9. Cashman JD, Lapidot T, Wang JC, et al. Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice. *Blood*. 1997;89:4307-4316.
10. Bhatia M, Bonnet D, Wu D, et al. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. *J Exp Med*. 1999;189:1139-1148.
11. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. *Nat Immunol*. 2001;2:172-180.
12. Zanjani ED, Almeida-Porada G, Livingston AG, Flake AW, Ogawa M. Human bone marrow CD34+ cells engraft in vivo and undergo multilineage expression that includes giving rise to CD34+ cells. *Exp Hematol*. 1998;26:353-360.
13. Bhatia M, Bonnet D, Murdoch B, Gan OI, Dick JE. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. *Nat Med*. 1998;4:1038-1045.
14. Guenetha G, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. *Nature Immunol*. 2001;2:75-82.
15. Glimm H, Bisterer W, Lee K, et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice. *J Clin Invest*. 2001;107:199-206.
16. Grier H, Civin C. Acute and chronic myeloproliferative disorders and myelodysplasia. In Nathan D, Oski F, eds. *Hematology of Infancy and Childhood*. Vol. 2 (ed 4). Philadelphia: W.B. Saunders Company; 1993:12:8-1318.
17. Griffin J, Löwenberg B. Clonogenic cell in acute myeloblastic

- leukemia. *Blood*. 1986;68:1185-1195.
18. McCulloch E. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture). *Blood*. 1983;62:1.
 19. Dick JE. Assays for human leukemic stem cells. *Hematology*. 1999;112:119.
 20. Fralkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: Heterogeneity of stem cell origin. *Blood*. 1981;57:1068-1073.
 21. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nature*. 1997;387:320-327.
 22. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature*. 1994;367:645-648.
 23. Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. *Leukemia*. 2000;14:889-897.
 24. Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR. *Blood*. 1998;92:4325-4335.
 25. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. *Blood*. 1997;89:3104-3112.
 26. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. *Leukemia*. 2000;14:1777-1784.
 27. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). *Exp Hematol*. 2000;28:660-671.
 28. Terpstra W, Pijns A, Ploemacher RE, et al. Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. *Blood*. 1996;87:2187-2194.
 29. Goodell M, Rosenzweig M, Kim H, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. *Nature Med*. 1997;3:1337-1345.
 30. Feuring-Buske M, Hogge DE. Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)/CD38(-) progenitor cells from patients with acute myeloid leukemia. *Blood*. 2001;97:3882-3889.
 31. Turhan AG, Lemoine FM, Debert C, et al. Highly purified primitive hematopoietic stem cells are PML-RAR α negative and generate monoclonal progenitors in acute promyelocytic leukemia. *Blood*. 1995;85:2154-2161.
 32. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. *N Engl J Med*. 1989;320:828-834.
 33. Robinson N, Sanders JE, Benyunes MC, et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. *Blood*. 1996;87:1249-1254.
 34. de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. *J Immunol*. 1992;149:1788-1794.
 35. Dolstra H, Fredrix H, Proljers R, et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. *J Immunol*. 1997;158:560-565.
 36. Warren EH, Gavin M, Greenberg PD, Riddell SR. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. *Curr Opin Hematol*. 1998;5:429-433.
 37. Falkenburg JH, Goslink HM, van der Harst D, et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. *J Exp Med*. 1991;174:27-33.
 38. Niederwieser D, Grassegger A, Aubock J, et al. Correlation of minor histocompatibility antigen-specific cytotoxic T lymphocytes with graft-versus-host disease status and analyses of tissue distribution of their target antigens. *Blood*. 1993;81:2200-2208.
 39. Faber LM, van der Hoeven J, Goulmy E, et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. *J Clin Invest*. 1995;96:877-883.
 40. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. *Proc Natl Acad Sci U S A*. 1999;96:8639-8644.
 41. Rozenmiller H, Terpstra W, Rombouts EJ, et al. GM-CSF receptor targeted treatment of primary AML in SCID mice using Diphtheria toxin fused to huGM-CSF. *Leukemia*. 1998;12:1962-1970.
 42. Hall PD, Willingham MC, Kreitman RJ, Frankel AE. DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. *Leukemia*. 1999;13:629-633.
 43. Pereira DS, Dorrell C, Ito CY, et al. Retroviral transduction of TLS-ERG initiates a leukemogenic program in normal human hematopoietic cells. *Proc Natl Acad Sci U S A*. 1998;95:8239-8244.
 44. Kerre TC, De Smet G, De Smedt M, et al. Both CD34(+)/38(+) and CD34(+)/38(-) cells home specifically to the bone marrow of NOD/LtSz scid/scid mice but show different kinetics in expansion. *J Immunol*. 2001;167:2177-9.
 45. Guzman ML, Upchurch D, Grimes B, et al. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. *Blood*. 2001;98:2177-9.
 46. Wulf GG, Wang RY, Kuehale I, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. *Blood*. 2001;15:1166-73.



STEM CELLS®

**New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation
Induction—Present Use and Future Possibilities**
Øystein Bruserud and Bjørn Tore Gjertsen
Stem Cells 2000;18:157-165
DOI: 10.1634/stemcells.18-3-157

This information is current as of September 3, 2006

The online version of this article, along with updated information and services, is located on
the World Wide Web at:
<http://www.StemCells.com/cgi/content/full/18/3/157>

STEM CELLS®, an international peer-reviewed journal, covers all aspects of stem cell research: embryonic stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell genetics and genomics; translational and clinical research; technology development.

STEM CELLS® is a monthly publication, it has been published continuously since 1983. The Journal is owned, published, and trademarked by AlphaMed Press, 318 Blackwell Street, Suite 260, Durham, North Carolina, 27701. © 2000 by AlphaMed Press, all rights reserved. Print ISSN: 1066-5099. Online ISSN: 1549-4918.

AlphaMed Press

Downloaded from www.StemCells.com by on September 3, 2006



New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities

ØYSTEIN BRUSERUD, BJØRN TORE GJERTSEN

Section for Hematology, Department of Medicine, Haukeland University Hospital;
Institute of Anatomy and Cell Biology, University of Bergen, Bergen, Norway

Key Words. *Acute myelogenous leukemia · Differentiation · Apoptosis · Immunotherapy*

ABSTRACT

A differentiation block and an accumulation of immature myeloid cells characterize acute myelogenous leukemia (AML). However, native AML cells usually show some morphological signs of differentiation that allow a classification into different subsets, and further differentiation may be induced by exposure to various soluble mediators, for example, all-trans retinoic acid (ATRA) and several cytokines. Combination therapy with ATRA and chemotherapy should now be regarded as the standard treatment of the acute promyelocytic leukemia (APL) variant of AML. Although several agents can also induce leukemic cell differentiation for other AML subgroups, in vitro studies as well as clinical data have demonstrated that these agents often have heterogeneous effects on the leukemic progenitors. This makes the clinical impact of differentiation induction therapy for individual patients difficult to predict. However, differentiation induction

should be regarded as a promising therapeutic approach, especially as a part of immunotherapy or in combination with intensive chemotherapy to increase the susceptibility of AML blasts to drug-induced apoptosis. Although the morphology-based French-American-British classification was used to identify APL as an AML subset that required a special treatment, it seems unlikely that this classification alone can be used to identify new subsets of AML patients with special therapeutic requirements. Future studies on differentiation induction in AML should therefore focus on A) the identification of therapeutic agents with more predictable effects; B) the use of clinical and laboratory parameters to define new subsets of AML patients in which differentiation induction has a predictable and beneficial effect, and C) the characterization of how AML blast sensitivity to drug-induced apoptosis is altered by differentiation induction. *Stem Cells* 2000;18:157-165

INTRODUCTION

Acute myelogenous leukemia (AML) is characterized by a neoplastic proliferation of myeloid cells [1-8]. The malignant cells have a differentiation block that results in an accumulation of immature cells, and AML can thus be diagnosed: A) if at least 30% of nucleated cells in the bone marrow are myeloblasts (or alternatively 20%, [8]); B) in the case of bone marrow showing erythroid predominance, if at least 30% of nonerythroid cells are myeloblasts; or C) if the characteristic signs of hypergranular promyelocytic leukemia (acute promyelocytic leukemia, [APL]) are present [1, 2].

Cases of AML can be subclassified on the basis of morphology, cytochemistry, immunological markers, and/or

cytogenetics [1-5]. According to the widely accepted French-American-British (FAB) classification, AML can be divided into the following subclasses based on the differentiation of the malignant cells [1-5]: AML-M0 and -M1 show minimal differentiation; AML-M2 includes a minor maturing granulocytic component, whereas AML-M3 (APL) has a dominating accumulation of promyelocytes; AML-M4 and -M5 show myelomonocytic differentiation; AML-M6 has an erythroid predominance; and AML-M7 is the acute megakaryoblastic leukemia. Native AML blasts may also on rare occasions show basophilic or eosinophilic differentiation [6, 7]. These morphological criteria are also incorporated in the recently published World Health Organization classification of myeloid neoplasms [8]. For a

Correspondence: Øystein Bruserud, M.D., Ph.D., Department of Medicine, Haukeland Hospital, N-5021 Bergen, Norway. Telephone: 47-55-29-80-60; Fax: 47-55-97-29-50. Received March 1, 2000; accepted for publication March 2, 2000. ©AlphaMed Press 1066-5099/2000/\$5.00/0

STEM CELLS 2000;18:157-165 www.StemCells.com

Downloaded from www.StemCells.com by on September 3, 2006

subset of AML patients, the leukemia blasts even show functional evidence of differentiation and are capable of antibody-dependent attachment and internalization (phagocytosis) of bacteria as well as zymosane particles [9].

AML treatment usually includes intensive chemotherapy administered as A) induction treatment that aims to bring the patient into complete hematological remission, and B) consolidation therapy that aims to eradicate residual disease and prevent AML relapse [5]. Consolidation therapy with intensive chemotherapy alone or in combination with autologous stem cell transplantation is associated with a relatively high risk of AML relapse and an overall long-term AML-free survival of less than 50%, whereas consolidation with allogeneic transplantation has a lower relapse risk but a higher treatment-related mortality [5]. The addition of differentiation induction therapy with all-trans retinoic acid (ATRA) is now regarded as mandatory in the treatment of APL [10-13], and the use of differentiation induction as a therapeutic approach with low treatment-related morbidity and mortality is also considered for other AML patients.

DIFFERENTIATION INDUCTION IN THE TREATMENT OF APL

APL is characterized by the expansion of malignant myeloid cells blocked at the promyelocyte stage of differentiation. Several excellent reviews of the pathogenesis, diagnosis, and treatment of APL have recently been published [10-14], and we will only briefly comment on the clinical use of differentiation induction in APL. This AML subset is associated with reciprocal chromosomal translocations that involve the retinoic acid receptor α (RAR α) gene on chromosome 17q21 [10, 12, 13]. The RAR α most commonly fuses to the PML gene on chromosome 15q23, but in rare variants of APL the RAR α fuses with the promyelocytic leukemia zinc finger gene on chromosome 11q23, the nucleophosmin gene on chromosome 5q32, or the nuclear mitotic apparatus gene on chromosome 11q13. These translocations lead to fusion genes and the expression of aberrant chimeric proteins.

ATRA belongs to the retinoid family of vitamin A derivatives [10-14]. The retinoids exert important effects on cell development, proliferation, and differentiation, and their biological effects are mediated by the RAR and the retinoid X receptors (RXRs). Only the RARs can be activated by ATRA. The molecular mechanisms for the antileukemic effect of ATRA are probably complex and include ligand binding to PML-RAR α with degradation of fusion proteins and altered transcription regulation [12]. The effects of ATRA seem to differ in the various subsets of APL patients, and patients with t(11;17) have a worse prognosis and little or no effect of ATRA therapy [10, 12, 13].

Effects of ATRA in APL

The *in vitro* effects of ATRA have been characterized in detail both for AML cell lines (HL60 and NB4 cells) and native APL cells [10, 14]. The presence of ATRA during *in vitro* culture increases the fraction of differentiated cells with functional characteristics of normal neutrophils. ATRA will also increase cytokine secretion, induce a mature membrane molecule phenotype, inhibit leukemia cell proliferation, and induce apoptosis [14-18].

A number of phase II studies have also confirmed that ATRA induces complete remission and rapid resolution of the life-threatening bleeding complications in a majority of APL patients [10-14, 19], and this *in vivo* effect seems to be caused by true differentiation of the malignant cells with apoptosis as the final mechanism by which the leukemic clone is extinguished [14, 15, 18].

Induction therapy with ATRA followed by chemotherapy has been compared with chemotherapy alone in two large randomized studies [19, 20], and both studies demonstrated an increased long-term APL-free survival of patients treated with combination therapy. A recent randomized study has also demonstrated that the long-term APL-free survival is higher for patients who receive simultaneous combination therapy compared with sequential combination [21]. The advantage of simultaneous combinations seems to include better control of both the ATRA syndrome and the coagulopathy [10, 21]. In these three studies the chemotherapy was daunorubicin plus cytarabine, but nonrandomized studies suggest that cytarabine may be omitted from induction therapy in APL [22-24].

The recent randomized studies included two cycles of intensive postremission chemotherapy with daunorubicin plus cytarabine without ATRA [20, 21]. It should be mandatory that the consolidation therapy include an anthracycline; the benefit of cytarabine, however, has been questioned [10, 22-24]. APL patients also seem to benefit from some type of additional maintenance treatment that probably should include ATRA [20, 21, 24]. When APL treatment is based on these therapeutic principles, an event-free survival exceeding 75% at 2 years has been described [21].

Arsenic Derivatives as Differentiation-Inducing Agents in APL

In vitro studies have shown that certain arsenic derivatives are effective against APL cells, and a recent clinical study demonstrated that As₂O₃ should be regarded as a promising therapeutic agent with limited toxicity [25]. This agent seems to act as a differentiation and apoptosis inducer, and the results suggest a possible role of arsenic derivatives in consolidation and/or maintenance therapy [25].

Bruscia, Gjertsen

159

DIFFERENTIATION INDUCTION IN AML CELLS WITH NON-APL PHENOTYPE**Cytokine Effects on AML Blast Differentiation In Vitro**

Although the effects of various cytokines on AML cell (native blasts and AML cell lines) proliferation and viability have been extensively studied, relatively few studies have examined effects of single cytokines, cytokine combinations, or cytokines plus vitamin-D₃ on differentiation of native AML blasts [26-34]. Many of these studies are in addition relatively small, and the patients are often heterogeneous with regard to prognostic factors and FAB classification. However, the following conclusions are justified based on the representative studies summarized in Table 1: A) AML blasts can be induced to differentiate in several myeloid directions, and the same differentiation response can often be induced by different cytokines [26-34]; B) a certain cytokine or cytokine combination usually induces differentiation only for a subset of patients, and the direction of differentiation often varies between patients [27, 29]; C) differentiation induction can be independent of the effects

on blast proliferation, and D) the direction of differentiation often shows no correlation with FAB classification (i.e., previous signs of differentiation) [27, 29-31]. Thus, in contrast to the predictable effects of differentiation induction in APL, the effects in other AML subsets are difficult to predict in individual patients. The same conclusion was also drawn in a clinical study of interleukin 3 (IL-3) therapy in AML [35]. Future investigations of differentiation induction should therefore focus on A) the identification of new agents/combinations/procedures with more predictable effects, and B) the identification of patient subsets in which the effects are predictable and likely to be clinically beneficial.

Candidate Drugs for Differentiation Induction**Cytotoxic Drugs**

Anticancer agents (e.g., cytarabine, daunorubicin, 6-thioguanine) can induce differentiation in AML cell lines and in native AML blasts [36-39], and combinations of cytosine arabinoside or 6-thioguanine plus retinoic acid plus either hexamethylene or dimethylformamide seem to

Table 1. Differentiation induction in human AML cells cultured in vitro in the presence of soluble mediators: a summary of the results from representative studies...

| Direction of differentiation | Soluble mediators used | Detection of differentiation in native AML blasts | Reference |
|------------------------------|---|---|-----------|
| Neutrophil granulocyte | SCF or IL-3 | Induction of CD15 expression and promyelocyte-myelocyte morphology in CD34 ⁺ AML-M1/M2 blasts | 26 |
| | IL-3, G-CSF, or GM-CSF | Increased proportions of mature granulocytes for some patients, no correlation between differentiation induction and FAB class | 27 |
| | IFN- γ , TNF- α , Vit-D ₃ , or retinoic acid | Enhanced differentiation when G-CSF was combined with retinoic acid | 28 |
| | | Increased expression of CD15 and CD33 in subsets of patients together with decreased colony formation in clonogenic assay; these effects were caused by single agents and/or by combinations of mediators | 29 |
| Eosinophil granulocyte | SCF | Differentiation into myelocyte- and metamyelocyte-like leukemic cells with disappearance of CD34 and HLA-DR expression for a subset of patients | 30 |
| | IL-5 | Induction of either pure or mixed leukemic eosinophilic colonies, no correlation with FAB classification | 31 |
| Basophilic granulocyte | SCF | Differentiation into cells with segmented nuclei and basophilic/mazochromatic granules for a small minority of patients | 30 |
| Monocyte | IFN- γ , TNF- α , Vit-D ₃ , or retinoic acid | Increased membrane expression of the monocyte marker CD14 in subset of patients; effects were caused by single agents or combinations of mediators | 29 |
| | TNF- α | Induction of monocytic morphology with increased phagocytic capacity and expression of CD11b and CD14 | 32 |
| | IL-3, GM-CSF, G-CSF, or M-CSF | Increased number of AML cells with monocyte/macrophage morphology | 27 |
| | SCF | Induction of a macrophage-like morphology and expression of CD13, CD14, and HLA-class II in a minority of patients | 30 |
| | Leukemia inhibitory factor | Expression of the Wilms' tumor suppression gene together with monocyte differentiation in the M1 AML cell line | 35 |
| Megakaryocyte | Thrombopoietin + IL-3 or SCF | Increased expression of platelet-specific antigens in the M-07e AML cell line | 33 |
| Erythroid differentiation | Erythropoietin | Further erythroid differentiation for patients with erythroleukemia | 27 |

AML = acute myelogenous leukemia; SCF = stem cell factor; G-CSF = granulocyte colony-stimulating factor; GM-CSF = granulocyte-macrophage colony-stimulating factor; FAB = French-American-British; IFN- γ = gamma-interferon; TNF- α = tumor necrosis factor alpha.

induce AML blast differentiation even for a majority of patients [37-39]. This effect is observed at lower concentrations than are required for drug-mediated killing, and it probably involves drug-induced alterations in the cytokine responsiveness of AML cells [36].

Altered Histone Acetylation

Acetylation and deacetylation of histones are regarded as important for transcription activation and repression, respectively. Histone deacetylase inhibitors can induce differentiation in native AML blasts for a subset of patients, and they also cause a synergistic enhancement of ATRA-induced differentiation [40]. These effects show no correlation with previous signs of differentiation (i.e., FAB classification). Butyrates are another group of drugs that seem to induce gene expression via histone hyperacetylation, and monosaccharide butyrate derivatives can also induce differentiation in native AML blasts for a subset of patients [41].

High-Dose Methylprednisolone

Both in vitro and in vivo studies suggest that high-dose methylprednisolone (30 mg/kg/day) can induce differentiation of AML cells to mature granulocytes that subsequently die from apoptosis [42-44]. However, this treatment has been tried only in a few patients, and one should be very careful with the interpretation of these results.

Metal Chelators

In vitro exposure to the metal chelator diethylenetriamine will induce differentiation and apoptosis in the AML cell line ML-1 [45]. Although this drug is probably not suitable for clinical use due to its side effects, the results suggest that this new therapeutic approach may become useful in future therapy.

ATRA and Vitamin D₃ Analogs

Except for APL, ATRA and vitamin D₃ are not potent enough to provide clinical benefit when used at doses that can be tolerated by patients [46]. However, a recent study described that, although addition of ATRA to chemotherapy did not improve patient outcome, in vitro evidence for response to ATRA was detected in 25% of the patients [47]. In vitro studies have also demonstrated that the differentiation induction effects of ATRA, vitamin D₃, and/or vitamin D₃ derivatives can be enhanced by several other agents [48, 49], including the drug clofibrate acid, which has been used without serious side effects in hyperlipemic patients [48]. Thus, combination treatment with chemotherapy, ATRA, and ATRA-potentiating agents may become useful in AML.

Differentiation Induction and Regulation of Apoptosis

Drug-Induced Apoptosis in AML

In vitro studies have demonstrated that apoptosis can be induced in AML blasts by several cytotoxic drugs, including cytarabine [50-54], daunorubicin [54], etoposide [55], idarubicin [56], and 6-thioguanine [51]. Furthermore, clinical studies indicate that the expression of apoptosis-regulating molecules (bcl-2, Mcl-1, caspases) is important for the risk of relapse after chemotherapy [57-59]. Taken together these data suggest that the susceptibility of AML blasts to drug-induced apoptosis is important for the outcome after intensive chemotherapy in AML.

Bcl-2 Levels and Chemosensitivity

Studies of the AML cell line HL-60 have demonstrated that cells induced to differentiate toward neutrophils subsequently die via apoptosis [60]. A possible mechanism for induction of apoptosis is the reduction of the intracellular bcl-2 level, which is observed during differentiation of both HL-60 AML cells and normal myeloid progenitors [61]. There is also an association between high bcl-2 levels in AML cells and decreased sensitivity to drug-induced apoptosis [51-53], and for a subset of patients the inhibition of bcl-2 with antisense oligonucleotides will increase the sensitivity of native blasts to cytarabine-induced apoptosis [50]. This last observation suggests that bcl-2 is directly involved in the regulation of drug-induced apoptosis, possibly via intracellular pathways involving bcl-xL expression [52], prevention of caspase gene expression [55], and/or reduction of oxidant activity by toxic radicals [53]. These results also suggest that differentiation induction therapy may become useful in selected AML patients by increasing the blast sensitivity to drug-induced apoptosis.

The effect of ATRA on differentiation, bcl-2 levels, and chemosensitivity in AML blasts has been studied in AML cell lines. For certain cell lines ATRA can induce differentiation and reduce intracellular bcl-2 levels without altering the susceptibility to drug-induced apoptosis [56, 62]; for other cell lines an increased chemosensitivity seems to depend on G₀/G₁ cell-cycle arrest rather than the differentiation status or bcl-2 levels [56]; and for a last group of cell lines ATRA seems to increase chemosensitivity by downregulation of bcl-2 [53, 54]. ATRA can also downregulate bcl-2 expression in native AML blasts for a subset of patients independent of their FAB classification [63]. These effects of ATRA on bcl-2 seem to be mediated by different mechanisms, including regulation of transcription, altered phosphorylation, and decreased bcl-2 stability [54, 64]. The effects of ATRA on chemosensitivity can be

Bruserud, Gjertsen

161

further modulated by vitamin K analogs; many of these nontoxic analogs induce apoptosis and enhance effects of ATRA via a mechanism involving downregulation of bcl-2 and upregulation of Bax expression with concomitant activation of caspase-3 [65].

A recent study concluded that bcl-2 expression in AML blasts was not an independent prognostic factor in AML patients receiving intensive chemotherapy [66]. This in vivo observation thus seems to conflict with the in vitro results described above. However, the induction and timing of apoptotic events seem to be both cell type and inducer dependent [67], and various cytotoxic drugs seem to use different intracellular pathways for induction of apoptosis [51, 67]. These heterogeneities may explain the apparent discrepancy between the in vitro results and the available clinical data. Future studies therefore have to consider that A) the prognostic impact of high bcl-2 levels may differ between patients, and B) the impact of various prognostic factors (including bcl-2 expression) may also depend on the type of chemotherapy.

Expression of Tumor Suppressor Genes

The p53 tumor suppressor gene is an important regulator of apoptosis in AML blasts [68]. Recent studies suggest that certain conformational variants of p53, which occur either by mutation or by the action of hematopoietic growth factors, permit AML blast survival and are associated with a bad prognosis [69]. Decreased expression of the retinoblastoma tumor suppressor gene in the AML blasts is also associated with an increased risk of leukemia resistance or relapse [70]. Although the expression of both p53 and its negative regulator protein, MDM2, is associated with the differentiation status and is increased in AML blasts with a myelomonocytic phenotype (FAB-types M4/M5) [71], it is not known whether the expression or function of tumor suppressor molecules will be altered by differentiation induction therapy.

DIFFERENTIATION INDUCTION AND IMMUNOTHERAPY IN AML

AML blasts often have genetic abnormalities (e.g., mutations, translocations, inversions [4]) that encode abnormal proteins with leukemia-specific peptide sequences [72]. T cell recognition of such leukemia-specific epitopes has been detected for the t(9;21) (Philadelphia chromosome) and the t(15;17) (APL) translocations [73-75], and these observations support the hypothesis that enhancement of autologous antileukemic T cell reactivity is possible in AML.

Antigen-specific T cell recognition requires the presence of professional accessory cells with a dual function:

A) antigenic peptides have to be presented in the context of self-HLA before they can be recognized by specific T cells, and B) antigen-specific T cells need an additional costimulatory signal to become activated; in the absence of costimulation, specific T cell anergy may develop [72, 76]. Dendritic cells are considered as the most potent professional antigen-presenting cells [77]. Although native AML blasts with a phenotype consistent with progenitors of dendritic Langerhans' cells have been described [78], this phenotype seems to be very rare. Native AML blasts usually express only some of the membrane molecules needed for initiation of T cell activation, including the peptide-presenting HLA class I and class II molecules and the T cell binding CD58 molecule, but in most cases the AML blasts do not express the costimulatory B7 (CD80 and CD86) and CD45 molecules [72, 79]. One possible approach for enhancement of AML-specific T cell reactivity would therefore be to induce a dendritic cell phenotype in AML blasts, and thereafter to use these modulated cells for presentation of leukemia-specific antigens to T cells (Table 2). In vitro studies have demonstrated that AML blasts can be induced to differentiate into a dendritic cell phenotype by exposure to exogenous cytokines [80-84], and for a subset of patients coculture of autologous T lymphocytes with such AML-derived dendritic cells can induce a leukemia-specific T cell response [80, 82]. This patient heterogeneity is probably caused both by variation in the ability of AML blasts to acquire the dendritic cell phenotype, and by immunogenetic differences that result in T cell nonresponsiveness to leukemia-specific antigens in certain patients [75, 85].

CONCLUSION

At present, differentiation induction therapy is used only in the treatment of the AML-M3/API subset. Although in vitro studies have demonstrated that leukemia blasts derived from other AML patients may also be induced to differentiate, these effects are difficult to predict in individual patients. Future studies of differentiation induction in AML should therefore try to identify A) new agents or combinations of agents with more predictable effects; B) subsets of patients who are likely to benefit from differentiation induction, and C) cytotoxic drugs that can be used in combination with differentiation induction therapy.

ACKNOWLEDGMENTS

The study was supported by the Norwegian Cancer Society. The advice of Professor Peter Ernst is gratefully acknowledged.

Table 2. Induction of a dendritic cell (DC) phenotype in native AML blasts by exposure to exogenous cytokines; characterization of the experimental *in vitro* models [80-84]

| Experimental procedures | Differentiation induction and detection |
|--|---|
| Cytokine combinations used to induce a DC phenotype | Culture with GM-CSF + IL-4 for 10-14 days and addition of TNF- α or CD40-ligand the last 24 h [80] Culture for 3 days with either GM-CSF + IL-4 or GM-CSF + IL-4 + CD40-ligand cells [82] Culture for 1-5 days with GM-CSF + TNF- α + SCF + IL-6 [83] Cytokine combinations utilizing Flt3-L and IL-3 + terminal TNF- α , 3 days culture [84] Long-term culture (21 days) with GM-CSF + IL-4 + TNF- α [81] |
| Phenotypic characteristics of DC-AML blasts | Upregulated or induced expression of adhesion (CD54, CD58), costimulatory (CD80, CD86), and antigen-presenting (HLA class I and class II) molecules [80-84] Increased expression of the differentiation marker CD83 that is found on peripheral mature DC, whereas markers of the immature DC phenotype (CD1a, mannose receptor, E-cadherin) are rarely expressed [82] Downregulation of the monocyte marker CD14 [82] Increased secretion of IL-12 (a characteristic of mature DC) [82] Morphological changes with dendritic projections [80-84] |
| Accessory cell function during T cell activation with DC-AML cells | Autologous lymphocytes cultured with DC-AML cells show specific cytotoxicity against native, autologous AML blasts [80, 82] |

DC = dendritic cell; GM-CSF = granulocyte-macrophage colony-stimulating factor; SCF = stem cell factor; TNF- α = tumor necrosis factor alpha; SCF = stem cell factor; AML = acute myelogenous leukemia.

REFERENCES

- Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. *Br J Haematol* 1976;33:451-458.
- Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. *Ann Intern Med* 1985;103:620-625.
- Cheson BD, Cassileth PA, Head DR et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. *J Clin Oncol* 1990;8:813-819.
- Casasnovas RO, Campos L, Mugneret F et al. Immunophenotypic patterns and cytogenetic anomalies in acute non-lymphoblastic leukemia subtypes: a prospective study of 432 patients. *Leukemia* 1998;12:34-43.
- Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. *N Engl J Med* 1999;341:1051-1062.
- Duchayne E, Demur C, Robit H et al. Diagnosis of acute basophilic leukemia. *Leuk Lymphoma* 1999;32:269-278.
- Meessen HD, Runkl HJ, Rieder H et al. Distinction of eosinophilic leukaemia from idiopathic hypereosinophilic syndrome by analysis of Wilms' tumour gene expression. *Br J Haematol* 1998;101:325-334.
- Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting--Airlie House, Virginia, November 1997. *J Clin Oncol* 1999;17:3835-3849.
- Bassoe CF, Halstensen A, Bruserud Ø. Functional differentiation of acute myeloid leukaemia blast cells. *APMIS* 1999;107:1023-1033.
- Lo Coco F, Nervi C, Avvisati G et al. Acute promyelocytic leukemia: a curable disease. *Leukemia* 1998;12:1806-1880.
- Tallman MS. Differentiating therapy in acute myeloid leukemia. *Leukemia* 1996;10:1262-1268.
- Kogan SC, Bishop JM. Acute promyelocytic leukemia: from treatment to genetics and back. *Oncogene* 1999;18:5261-5267.
- He LZ, Merghoub T, Pandolfi PP. In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. *Oncogene* 1999;18:5278-5292.
- Gillis JC, Goa KL. Tretinoin. A review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukaemia. *Drugs* 1995;50:897-923.
- Chen ZX, Xue YQ, Zhang R et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. *Blood* 1991;78:1413-1419.
- Fenaux P, Castaigne S, Dombret H et al. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. *Blood* 1992;80:2176-2181.
- Kanamaru A, Takemoto Y, Tanimoto M et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. *Blood* 1995;85:1202-1206.
- Elliot S, Taylor K, White S et al. Proof of differentiation mode of action of all-trans retinoic acid in acute promyelocytic leukemia using X-linked clonal analysis. *Blood* 1992;79:1916-1919.
- Fenaux P, Le Delcy MC, Castaigne S et al. Effect of all-trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. *Blood* 1993;82:3241-3249.

Brasenud, Gjertsen

163

- 20 Tallman MS, Andersen JW, Schiffer CA et al. All-trans-retinoic acid in acute promyelocytic leukemia. *N Engl J Med* 1997;337:1021-1028.
- 21 Fenaux P, Chastang C, Chevret S et al. A randomized comparison of all-trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. *Blood* 1999;94:1192-1200.
- 22 Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Ematologico Maligne dell'Adulto (GIMEMA) pilot study. *Blood* 1996;88:1390-1398.
- 23 Estey E, Thall PF, Pierce S et al. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. *J Clin Oncol* 1997;15:483-490.
- 24 Sanz M, Martin G, Rayon C et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RAR α -positive acute promyelocytic leukemia. *Blood* 1999;94:3015-3021.
- 25 Niu C, Yan H, Yu T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed promyelocytic leukemia patients. *Blood* 1999;94:3315-3324.
- 26 Böhning HJ, Herbst R, Kostka G et al. Modulation of p145^{erbA} function in cells of patients with acute myeloblastic leukemia. *Cancer Res* 1993;53:4424-4431.
- 27 Salem M, Delwel R, Mahmoud LA et al. Maturation of acute myeloid leukemia in vitro: the response to five recombinant haematopoietic factors in a serum-free system. *Br J Haematol* 1989;71:363-370.
- 28 Santini V, Colombat P, Delwel R et al. Induction of granulocytic maturation in acute myeloid leukemia by G-CSF and retinoic acid. *Leuk Res* 1991;15:341-350.
- 29 Howell AL, Stukel TA, Bloomfield CD et al. Induction of differentiation in blast cells and leukemic colony-forming cells from patients with acute myeloid leukemia. *Blood* 1990;75:721-729.
- 30 Ikeda H, Kannaka Y, Furuta T et al. Changes in phenotype and proliferative potential of human acute myeloblastic leukemia cells in culture with stem cell factor. *Exp Hematol* 1993;21:1686-1694.
- 31 Motoji T, Okada M, Takanashi M et al. Abolition of suppressive effect of acute myeloid leukemia cells on normal granulocyte-macrophage colony formation induced by interleukin 5 associated with eosinophilic cell induction. *Leuk Lymphoma* 1995;18:171-178.
- 32 Bergamaschi G, Carlo-Stella C, Cazzola M et al. Tumor necrosis factor α down-regulates c-myc mRNA expression and induces in vitro monocytic differentiation in fresh blast cells from patients with acute myeloblastic leukemia. *Leukemia* 1990;4:426-430.
- 33 Hirai H, Shimazaki C, Yamagata N et al. Effects of thrombopoietin (c-mpl ligand) on growth of blast cells from patients with transient abnormal myelopoiesis and acute myeloblastic leukemia. *Eur J Haematol* 1997;59:38-46.
- 34 Gore SD, Weng LJ, Jones RJ et al. Impact on in vivo administration of interleukin 3 on proliferation, differentiation and chemosensitivity of acute myeloid leukemia. *Clin Cancer Res* 1995;1:295-303.
- 35 Smith SI, Weil D, Johnson GR et al. Expression of the Wilms' tumor suppressor gene, WT1, is upregulated by leukemia inhibitory factor and induces monocytic differentiation in M1 leukemic cells. *Blood* 1998;91:764-773.
- 36 Bloch A. Dynamics of interaction between DNA-specific anti-tumor agents and serum-contained cytokines in the induction of ML-1 human myeloblastic leukemia cell differentiation. *Leukemia* 1993;7:1219-1224.
- 37 Tawhid H, Rees J. Triple combination of retinoic acid + 6-thioguanine + hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture. *Leuk Res* 1990;14:109-117.
- 38 Hassan HT, Rees JK. Triple combination of retinoic acid + low concentrations of cytosine arabinoside + hexamethylene bisacetamide induces differentiation of human AML blasts in primary culture. *Hematol Oncol* 1989;7:429-440.
- 39 Hassan HT, Rees JK. Triple combination of retinoic acid + aclacinomycin A + dimethylformamide induces differentiation of human acute myeloid leukaemic blasts in primary culture. *Anticancer Res* 1989;9:647-651.
- 40 Kosugi H, Towatari M, Harano S et al. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to antileukemia therapy. *Leukemia* 1999;13:1316-1324.
- 41 Santini V, Scappini B, Gozzini A et al. Buryrate-stable monosaccharide derivatives induce maturation and apoptosis in human acute myeloid leukemia cells. *Br J Haematol* 1998;101:529-538.
- 42 Ozbeck N, Erdemli E, Hicsonmez G et al. Effects of methylprednisolone on human myeloid leukemic cells in vitro. *Am J Hematol* 1999;60:255-259.
- 43 Hicsonmez G, Erdemli E, Tekelioğlu M et al. Morphologic evidence of apoptosis in childhood acute myeloblastic leukemia treated with high-dose methylprednisolone. *Leuk Lymphoma* 1996;22:91-96.
- 44 Hicsonmez G, Tuncer M, Toksoy HB et al. Differentiation of leukemic cells induced by short-course high-dose methylprednisolone in children with different subtypes of acute myeloblastic leukemia. *Leuk Lymphoma* 1999;33:573-580.
- 45 Kahroki J, Muto N, Tanaka T et al. Induction of differentiation and apoptosis by difluzone in human myeloid leukemia cell lines. *Leuk Res* 1998;22:405-412.
- 46 Morosetti R, Koeffler HP. Differentiation therapy in myelodysplastic syndromes. *Semin Hematol* 1996;3:236-245.
- 47 Seiter K, Feldman EJ, Halicka HD et al. Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukemia. *Br J Haematol* 2000;108:40-47.

Downloaded from www.StemCells.com by on September 3, 2006

- 48 Fenton SL, Drayson MT, Hewison M et al. Clofibrate acid: a potential therapeutic agent in AML and MDS. *Br J Haematol* 1999;105:448-451.
- 49 Saito Y, Hatta H, Mano Y et al. Vitamin D3 analogue KH 1060 combined with TPA synergistically induces mature macrophages in human myeloblastic leukemia ML-1 cells. *Anticancer Res* 1999;19:1069-1076.
- 50 Keith FJ, Bradbury DA, Zhu YM et al. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. *Leukemia* 1995;9:131-138.
- 51 Balkham SE, Sargent JM, Elgie AW et al. Comparison of BCL-2 and BAX protein expression with in vitro sensitivity to ARA-C and 6TG in AML. *Adv Exp Med Biol* 1999;457:335-340.
- 52 Ibrado AM, Huang Y, Fang G et al. Overexpression of bcl-2 or bcl-xL inhibits Ara-C induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. *Cancer Res* 1996;56:4743-4748.
- 53 Hu ZB, Yang GS, Li M et al. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. *Leukemia* 1995;9:789-798.
- 54 Hu ZB, Minden MD, McCulloch EA. Post-transcriptional regulation of bcl-2 in acute myeloblastic leukemia: significance for response in chemotherapy. *Leukemia* 1996;10:410-416.
- 55 Droin N, Dubrez L, Eymen B et al. Upregulation of CASP genes in human tumor cells undergoing etoposide-induced apoptosis. *Oncogene* 1998;16:2885-2894.
- 56 Ketley NJ, Allen PD, Kelsey SM et al. Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25 (OH)₂ vitamin D3, and granulocyte-macrophage colony-stimulating factor. *Blood* 1997;90:4578-4587.
- 57 Kaufmann SH, Karp JE, Svignen PA et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemia relapse. *Blood* 1998;91:991-1000.
- 58 Maung ZT, MacLennan FR, Reid MM et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. *Br J Haematol* 1994;88:105-109.
- 59 Estrov Z, Thall PF, Talpaz M et al. Caspase 2 and caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. *Blood* 1998;92:3090-3097.
- 60 Martin SJ, Bradley JG, Cotter TG. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. *Clin Exp Immunol* 1990;79:448-453.
- 61 Delia D, Aiello A, Soligo D et al. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. *Blood* 1992;79:1291-1298.
- 62 Brudel A, Benoit G, De Nay D et al. Distinct apoptotic responses in maturation sensitive and resistant (t15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and Bcl-2 expression. *Leukemia* 1995;9:1173-1184.
- 63 Pisani F, Del Poeta G, Aronica G et al. In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. *Ann Hematol* 1997;75:145-147.
- 64 Hu ZB, Minden MD, McCulloch EA. Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid. *Blood* 1998;92:1768-1775.
- 65 Yaguchi M, Miyazawa K, Katagiri T et al. Vitamin E2 and its derivatives induce apoptosis in leukemia cells and enhance the effects of all-trans retinoic acids. *Leukemia* 1997;11:779-787.
- 66 Campos L, Oriol P, Sabido O et al. Simultaneous expression of P-glycoprotein and BCL-2 in acute myeloid leukemia blast cells. *Leuk Lymphoma* 1997;27:119-125.
- 67 Zheng A, Mantymaa P, Saily M et al. An association between mitochondrial function and all-trans retinoic acid-induced apoptosis in acute myeloblastic leukaemia cells. *Br J Haematol* 1999;105:215-224.
- 68 Olson I, Bergh G, Ehinger M et al. Cell differentiation in acute myeloid leukemia. *Eur J Haematol* 1996;57:1-16.
- 69 Zhu YM, Bradbury DA, Russell NH. Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. *Br J Cancer* 1994;69:463-472.
- 70 Kornblau SM, Xu HJ, Zhang W et al. Levels of tinotblastoma protein expression in newly diagnosed acute myelogenous leukemia. *Blood* 1994;84:256-261.
- 71 Seliger B, Papadimitris S, Vogel D et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. *Eur J Haematol* 1996;57:230-240.
- 72 Bruerud Ø. Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies. *Leukemia* 1999;13:1175-1187.
- 73 Gambacorti-Passerini C, Grignani F, Aricenti F et al. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARα present in acute promyelocytic leukemic cells. *Blood* 1993;81:1369-1375.
- 74 ten Bosch GJA, Joosten AML, Kessler JH et al. Recognition of BCR-ABL positive leukemia blasts by human CD4⁺ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. *Blood* 1996;88:3522-3527.
- 75 Pawelec G, Max H, Halder T et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. *Blood* 1996;88:2114-2124.
- 76 Schulze J, Nadler LM, Gribben JG. B7-mediated costimulation and the immune response. *Blood Rev* 1996;10:111-127.
- 77 Gluckman JC, Canque B, Chapuis F et al. In vitro generation of human dendritic cells and cell therapy. *Cytokine Cell Mol Ther* 1997;3:187-196.
- 78 Srivastava BI, Srivastava A, Srivastava MD. Phenotype, genotype and cytokine production in acute leukemia involving progenitors of dendritic Langerhans' cells. *Leuk Res* 1994;18:499-511.
- 79 Hirano N, Takahashi T, Takahashi T et al. Expression of costimulatory molecules in human leukemias. *Leukemia* 1996;10:1168-1176.
- 80 Choudhury BA, Liang JC, Thomas EK et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T cell responses. *Blood* 1999;93:780-786.

Bruscrud, Gjarsen

165

- 81 Cignetti A, Bryant E, Allione B et al. CD34⁺ acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. *Blood* 1999;94:2048-2055.
- 82 Charbonnier A, Gaugler B, Sainry D et al. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. *Eur J Immunol* 1999;29:2567-2578.
- 83 Santiago-Schwartz F, Coppock DL, Hindenburg AA et al. Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in acute myeloid leukemia. *Blood* 1994;84:3054-3062.
- 84 Panoskaltsis N, Belanger T, Rosell K et al. Optimal cytokine stimulation for the enhanced generation of leukemic dendritic cells: a novel strategy for adoptive immunotherapy of leukemia. *Blood* 1998;92(suppl 1):618a.
- 85 Bocchia M, Wentworth PA, Soutwood S et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. *Blood* 1995;85:2680-2684.

**New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation
Induction—Present Use and Future Possibilities**

Øystein Bruserud and Bjørn Tore Gjertsen

Stem Cells 2000;18:157-165

DOI: 10.1634/stemcells.18-3-157

This information is current as of September 3, 2006

**Updated Information
& Services**

including high-resolution figures, can be found at:
<http://www.StemCells.com/cgi/content/full/18/3/157>

 **AlphaMed Press**

Downloaded from www.StemCells.com by on September 3, 2006

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.